University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
2012

Evolutionary Dynamics of Neoplastic Cell Populations in Barrett's
Esophagus
Rumen Lyubenov Kostadinov
University of Pennsylvania, rkostadi@gmail.com

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Genetics Commons, and the Medicine and Health Sciences Commons

Recommended Citation
Kostadinov, Rumen Lyubenov, "Evolutionary Dynamics of Neoplastic Cell Populations in Barrett's
Esophagus" (2012). Publicly Accessible Penn Dissertations. 531.
https://repository.upenn.edu/edissertations/531

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/531
For more information, please contact repository@pobox.upenn.edu.

Evolutionary Dynamics of Neoplastic Cell Populations in Barrett's Esophagus
Abstract
Cancer is a disease that develops over decades as result of acquisition of abnormalities in the genomes
of otherwise normal cells. Acquired genomic heterogeneity in populations of cells within tissues allows
cell-level Darwinian evolution that selects abnormal cellular genotypes encoding neoplastic (new benign
growth), and in some cases cancerous (invasion within tissues and metastasis across tissues) cellular
phenotypes. I studied neoplastic evolution over time in vivo in the pre-malignant condition Barrett's
esophagus to address the puzzling clinical phenomenon that 90-95% of individuals with Barrett's stay
benign over decades compared to the remaining 5-10% who progress to esophageal adenocarcinoma.
Some individuals with Barrett's use aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) that
have been shown to reduce mortality from esophageal adenocarcinoma. I collaborated with the Seattle
Barrett's Esophagus Research Program group to test the hypothesis that NSAIDs modulate genome
evolution of neoplastic cells by reducing the acquisition rate of somatic genomic abnormalities (SGA). We
used single nucleotide polymorphism (SNP) arrays to detect SGA, such as copy number abnormalities
and loss of heterozygosity, in 161 biopsies from 13 individuals with Barrett's, obtained over 5-8 time
points during 6-19 years of follow-up care. Over the follow-up period, each individual had a single change
in NSAID use, allowing us to compare acquisition of SGA during periods on NSAIDs versus periods off
NSAIDs within individuals. We found that the rate of accumulation of SGA was significantly lower
(typically ten-fold lower) during periods on NSAIDs versus periods off NSAIDs. We also found that
typically 1-3% of the genome had acquired SGA at baseline and that this percentage did not increase
significantly over decades. In one individual who progressed to esophageal adenocarcinoma we detected
a clonally expanded subpopulation of cells within the Barrett's tissue, which had massive SGA affecting
19% of the genome in the last 3 of 11 years of follow-up. In summary, these findings suggest that NSAID
use may reduce SGA acquisition rate and that neoplastic cell populations in Barrett's can maintain
evolutionary stasis over decades potentially explaining why 90-95% of individuals with Barrett's remain
benign and never progress to esophageal adenocarcinoma.
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ABSTRACT
EVOLUTIONARY DYNAMICS OF NEOPLASTIC CELL POPULATIONS
IN BARRETT’S ESOPHAGUS
Rumen Kostadinov
Carlo Maley
Cancer is a disease that develops over decades as result of acquisition of abnormalities in the
genomes of otherwise normal cells. Acquired genomic heterogeneity in populations of cells
within tissues allows cell-level Darwinian evolution that selects abnormal cellular genotypes
encoding neoplastic (new benign growth), and in some cases cancerous (invasion within
tissues and metastasis across tissues) cellular phenotypes. I studied neoplastic evolution over
time in vivo in the pre-malignant condition Barrett’s esophagus to address the puzzling
clinical phenomenon that 90-95% of individuals with Barrett’s stay benign over decades
compared to the remaining 5-10% who progress to esophageal adenocarcinoma. Some
individuals with Barrett’s use aspirin and other non-steroidal anti-inflammatory drugs
(NSAIDs) that have been shown to reduce mortality from esophageal adenocarcinoma. I
collaborated with the Seattle Barrett’s Esophagus Research Program group to test the
hypothesis that NSAIDs modulate genome evolution of neoplastic cells by reducing the
acquisition rate of somatic genomic abnormalities (SGA). We used single nucleotide
polymorphism (SNP) arrays to detect SGA, such as copy number abnormalities and loss of
heterozygosity, in 161 biopsies from 13 individuals with Barrett’s, obtained over 5-8 time
points during 6-19 years of follow-up care. Over the follow-up period, each individual had a
single change in NSAID use, allowing us to compare acquisition of SGA during periods on
v

NSAIDs versus periods off NSAIDs within individuals. We found that the rate of
accumulation of SGA was significantly lower (typically ten-fold lower) during periods on
NSAIDs versus periods off NSAIDs. We also found that typically 1-3% of the genome had
acquired SGA at baseline and that this percentage did not increase significantly over decades.
In one individual who progressed to esophageal adenocarcinoma we detected a clonally
expanded subpopulation of cells within the Barrett’s tissue, which had massive SGA
affecting 19% of the genome in the last 3 of 11 years of follow-up. In summary, these
findings suggest that NSAID use may reduce SGA acquisition rate and that neoplastic cell
populations in Barrett’s can maintain evolutionary stasis over decades potentially explaining
why 90-95% of individuals with Barrett’s remain benign and never progress to esophageal
adenocarcinoma.
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Chapter 1. Introduction
1.1. Progression of Barrett’s esophagus to esophageal adenocarcinoma
This doctoral dissertation relates to a pressing human need – to cure cancer. Cancer is a
disease that can end a human life prematurely. A research study by the American Cancer
Society estimates that, in the year 2012, 1,638,910 people would be diagnosed with cancer
and 577,190 people would die from cancer in the U.S., or stated simply, nearly one of every
four deaths in the U.S. is associated with cancer [1]. In this work, I investigate the
phenomenon of within-individual change in the genome of neoplastic cell
populations over time and I investigate and suggest ways to control somatic genomic
change over time to prevent cancer and extend human health span. I hypothesize that
the genomes of normal and neoplastic cells acquire somatic genomic abnormalities gradually
over time resulting in progressive transformation to invasiveness and malignancy.
Throughout this work, I examine the somatic genomic change over time in neoplastic cell
populations through evolutionary lens by adhering to clonal evolutionary theory [2]
according to which neoplastic cell populations evolve by acquisition of somatic genomic
change permitting Darwinian natural selection of variant cell lineages. I hypothesize that
measuring somatic genomic evolutionary dynamics of neoplastic cell populations within
individuals with Barrett’s esophagus would help distinguish individuals at low and high risk
of progression to esophageal adenocarcinoma that would help prevent overdiagnosis and
overtreatment in low-risk individuals and underdiagnosis and undertreatment in high-risk
individuals.
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Does carcinogenesis have clearly defined stages? Berenblum first described quantitatively in
mouse that the process by which cells become hyperplastic, that is, acquiring overgrowth
compared to neighboring normal cells, can be divided into two stages, “initiation” and
“promotion”, where cells can be initiated by application of a carcinogen, but they may lay
latent or dormant within the tissue, unless a distinct promoting agent triggers clonal
expansion manifesting hyperplasia [3]. Moreover, Berenblum demonstrated that distinct
chemical carcinogens vary in their ability initiating and promoting abilities [3]. Individuals
with Barrett’s esophagus enter clinical management after being symptomatic, and biopsies
are collected only if a Barrett’s segment is already present, thus we can never observe the in
vivo initiation of Barrett’s neoplasia and can only infer the elapsed time since initiation
indirectly based on initiation hypotheses and modeling assumptions. Foulds first described
the term “progression”, in the context of chemical carcinogenesis in model organisms, where
progression can be thought of as a distinct stage in neoplastic development marked by
karyotypic alterations in cell genotype and increased cellular growth rate, invasiveness, and
metastasis in cell phenotype [4]. My studies are limited to observing the genomic changes of
already hyperplastic and neoplastic cells over time, or the promotion, and in only one case
the promotion and progression phases in neoplastic evolution in Barrett’s esophagus and its
progression to esophageal adenocarcinoma.
My doctoral thesis seeks to shift the target of interventions from targeting individual genes
to targeting the dynamics of the whole genome. By characterizing the whole genome I aim
towards a holistic approach to the problem by measuring evolutionary biology parameters,
such as mutation rate, clonal expansion rate, magnitude of genetic diversity over time,
phylogenetic tree imbalance, etc., and associating such measures with clinical variables as
2

opposed to aiming towards a reductionist approach by associating abnormalities in individual
genes with clinical variables. Can we prevent some cancers by lowering the rate of genomic
changes or the clonal expansion rate of genetically unstable clones? The field is ripe for such
a change because, although somatic evolution is widely accepted as the theory of cancer, the
tools from evolutionary biology for studying that process have not yet been widely adapted
to study and prevent cancer. In my view, a theory of cancer would not be complete without
pairing theoretical models of genome dynamics over time with experimental in vivo
observations of genome dynamics over time in human biopsy specimens.
1.2. Barrett’s esophagus biology
Barrett’s esophagus (BE) is a condition of the distal esophagus in which the normal stratified
squamous epithelium is replaced by columnar epithelium with intestinal metaplasia [5]. BE is
thought to develop as complication of chronic gastroesophageal reflux disease (GERD) and
individuals with BE are at increased risk of progression to esophageal adenocarcinoma (EA):
1-7 persons with BE progress to EA per 1000 person-years [6,7]. Scientific progress is
providing new understanding of previously puzzling phenomena. The puzzling
phenomenon in Barrett’s esophagus is why 90-95% of individuals with BE follow a
benign course and never develop EA, and accordingly why the remaining 5-10% of
individuals do progress to EA. I investigate this phenomenon by investigating the whole
genome of Barrett’s neoplastic cells from biopsies collected from 13 individuals over 6-19
years, with the hypothesis that the change in the number of acquired somatic genomic
alterations over time may provide an insight into the phenomena of retaining a benign
course over decades versus developing malignancy.
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Reid, Kostadinov, and Maley suggested new strategies for clinical management of Barrett’s
esophagus by integrating clonal evolutionary theory into clinical diagnosis and practice [8].
The current and novel paradigms in the biology of Barrett’s metaplasia are summarized in
Figure.

Figure 1.1. Barrett's specialized intestinal metaplasia and mucosal defense. Barrett's
metaplasia arises in an environment of chronic reflux in which the distal esophagus is
exposed to high levels of local and systemic damage from acid, bile, and tobacco products,
as well as inflammatory responses to the injury [5,9–14]. All are mutagenic. Barrett's
metaplasia has a number of defenses against this mutagenic environment that are not found
in esophageal squamous epithelium [5,15]. A, Barrett's metaplasia secretes anions, including
bicarbonate, that participate in buffering acid reflux [16]. B, Barrett's metaplasia is a well
differentiated epithelium with crypt architecture in which putative stem cells residing at the
base give rise to proliferating transient amplifying cells and differentiated cells that are
4

sloughed into the lumen. This architecture has been proposed to be tumor-suppressive
because mutations in transient amplifying or differentiated non-stem cells will be shed from
the body before they can accumulate the serial mutations that lead to cancer [17]. C, Barrett's
metaplasia secretes a thick adherent mucus that is not present in squamous esophageal
epithelium for defense against acid and bile reflux [18–21]. D, Barrett's esophageal cells
maintain physiological intracellular pH after prolonged and repeated reflux exposure [22]. E,
The tight junctions of Barrett's metaplasia overexpress claudin 18 and several other claudins
(including claudins 1, 4, 12, and 23) that provide protection against acid permeation [23]. F,
A combined expression and proteomics study of Barrett's metaplasia reported
overexpression of genes involved in mucosal defense and repair [24]. Figure and figure
legend adapted from Reid et.al. [8].
The British oncologist Willis defined the essence of a neoplasm as “A neoplasm … the
growth of which persists in the same excessive manner after cessation of the stimuli which
evoked the change” [25]. The persistence of Barrett’s metaplasia in the esophagi of BE
individuals fits this description of a neoplasm, where whichever stimuli first evoked the
replacement of multi-layer squamous epithelium to single-layer columnar epithelium
(metaplasia) the cessation of such stimuli, by acid suppression medications or anti-reflux
surgery do not appear to result in regression of the Barrett’s segment. I hypothesize that the
persistence of Barrett’s metaplasia can be explained by irreversible genomic changes, where a
genome that has lost genomic information by deletion and loss of heterozygosity, cannot
regain such information back to revert back to expressing normal function. I evaluated the
length of the Barrett’s segment length over decades of follow -up time in 248 individuals with
Barrett’s participating in the Seattle Barrett’s Esophagus Research Program. I found that the
segment length remains 5.7 ± 3.6cm (mean ± standard deviation) long over decades (Figure
1.2) that shows both the persistence of this tissue despite acid suppressive medications, and
the relative constancy in the neoplastic cell population size of a Barrett’s segment.
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Figure 1.2. Typical Barrett’s segment length remains about 5cm during endoscopic
surveillance. Segment length data over time represents 248 individuals with BE from the
Seattle Barrett’s Esophagus Program cohort. Each point represents an estimate of the
distance between measured lower esophageal sphincter (LES) and ora serrata (OS) that are
recorded at an endoscopy (out of 489 total) and that are proxies for the extent of the
Barrett’s segment. Over all 489 endoscopies, the typical Barrett’s segment length measures
5.7 ± 3.6cm (mean ± s.d) and linear (blue line) and local weighted linear regressions (red
curve) show that segment lengths stay relatively constant over time.

The following chapters explore the genomic changes and evolutionary dynamics of
neoplastic cells occurring within BE tissues having this apparent constancy in length over
time. The word neoplasm is concisely defined as “tumor; any new and abnormal growth,
specifically one in which cell multiplication is uncontrolled and progressive” and the word
cancer is concisely defined as “a neoplastic disease the natural course of which is fatal” [26].
These two definitions capture the fundamental biology of cancer as a disease, namely the
phenomenon of uncontrolled and progressive overgrowth of cell populations that may have
a fatal outcome. These two definitions also present the crux of what I define as the cancer
diagnosis problem: Can we diagnose neoplasms (tumors) and predict which ones
6

would develop into malignant cancers that have a fatal natural course and which
ones would instead stay benign and not be fatal?
1.3. The application of evolutionary theory to cancer
While the Dorland medical dictionary refers to the cancer disease as having a “natural
course”, I conceptualize the cancer disease as having an “evolution”, that is, a somatic cell
level theory of Darwinian evolution, or viewing the cancer disease development as an
evolutionary and ecological process [27]. Charles Darwin put forward that the mechanism of
evolution is natural selection, which has three requirements: 1) variation in a population of
individuals 2) such variation must be heritable, and 3) such heritable variation must confer
differential fitness, i.e. a heritable trait that confers better reproductive or survival advantage
to individuals would increase in frequency in the population over several generations.
However, Darwin avoided the term evolution and instead preferred to use the term “descent
with modification” possibly because evolution implied a pre-charted trajectory or a
premeditated point to be reached by an evolving biological species. Instead of defining
neoplastic evolution as “a process of change in a certain direction”, I limit neoplastic
evolution to also mean “descent with modification” implying that the process itself is
inherently random and no premeditated endpoint exists and no trajectory of evolution’s
course can be predicted. In other words, neoplastic evolution in Barrett’s esophagus does
not necessarily have to have a premeditated adenocarcinoma endpoint. In cancer, “descent
with modification” describes the process by which somatic cell populations evolve or
descend with modification by the mechanism of natural selection. Natural selection applies
to somatic cell populations since they can: 1) acquire somatic genomic abnormalities (SGAs),
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such as DNA point mutations, copy number alterations, and structural chromosomal
rearrangements, 2) such SGAs are heritable over generations since cells divide asexually by
mitosis that copies SGAs from a parent cell’s DNA to a daughter cell’s DNA, and 3) such
heritable SGAs can confer differential fitness to cells that bear them, i.e. survival or
reproductive advantages manifested by abnormal overproliferative somatic cell phenotypes.
Acquisition of SGAs alters the genomes of normal somatic cells within somatic tissues and
by the mechanism of natural selection normal somatic cell populations can evolve
hyperplasia, neoplasia, and malignancy by selfishly increasing in numbers, or increasing
fitness relative to neighboring normal cells. Neoplastic cell populations that acquire SGA
begin exhibiting one or more of the cell phenotypes (“hallmarks”) of cancer by altering the
molecular pathway networks of somatic cell homeostatic cell growth, cell death, and cell
designated tissue function [28].
1.4. The theory of clonal evolution, or the theory of the genetics of neoplastic
development
To begin with, I will define some terms from my point of view. The neo-Darwinian
synthesis brings together Darwin’s theory of descent with modification and Mendelian
genetics. Population genetics is a field of study that rapidly advanced since the neoDarwinian synthesis and shifted focus from individual thinking to population thinking.
Mathematical population genetics provides a theoretical framework for describing the
changes in the genetic constitution of populations over time, most notably, changes in allele
frequencies over time. Phylogenetics can be categorized as a subfield of population genetics,
which is primarily concerned with estimating the morphologic (phenotypic) or genetic
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(genotypic) relatedness among species in a population of species or among individuals in a
population of individuals. Evolutionary dynamics is the process of change over time in a
population of individual entities that can evolve, i.e. the change in certain characteristics of
the population as result of the processes of mutation, natural selection, and migration
(expansion in space) over time within the population.
Several scientific advancements put forward evolutionary thinking as it relates to neoplastic
development. Theodor Boveri first theorized that SGA may underlie neoplastic growth by
observing in frog embryos multipolar mitoses that caused improper segregation of DNA to
daughter cells and resulted in the generation of genetic variation and phenotypic
abnormalities [29]. Later, in early cytogenetic studies Peter Nowell discovered the
Philadelphia chromosome, a common chromosomal rearrangement in chronic myeloid
leukemias and suggested in 1976 that “the acquired genetic variability permits stepwise
selection of variant cell lineages that underlies tumor progression”, which became known as
the clonal evolution theory of neoplastic progression [2]. In 2006, Merlo et al. reviewed
multiple studies to support the notion that neoplastic progression is an evolutionary and an
ecological process [27] suggesting that clonal evolution theory has survived challenges for
more than 40 years and can be thought of as the underlying theory of cancer.
Tumor genetic heterogeneity and aberrant karyotype (aneuploidy) is a ubiquitous observation
in primary tumors and metastatic cancers. Maley et al. showed that increased genetic
diversity in BE is associated with increased risk of progression to EA [30]. Merlo reviewed
the role of measuring genetic diversity in cancer [31]. Two studies by Park et al. showed that
increased genetic heterogeneity in breast cancer was associated with poor clinical outcomes
[32,33]. Leedham et al. showed individual crypt heterogeneity within Barrett’s segments by
9

using LOH markers and p16 and p53 sequence data [34]. A recent study by Beroukhim et al.
of 3131 cancer specimens from 26 histologic types showed widespread somatic genomic
alterations (SGA) involving both focal and chromosome-wide regions of the genome: 75,700
copy number gains and 55,101 copy number losses were identified, covering an average of
17% and 16% of the genomes, respectively, in cancer samples, compared to an average of
0.35% and 0.1% in normal samples [35]. Vogelstein and colleagues advanced a chromosomal
instability theory underlying cancer development [36–40]. Despite the recent massive
accumulation of data on genetic alterations in cancers, the process of somatic genomic
evolution that leads to cancer is severely understudied, even though it is the driving force for
neoplastic progression. The challenge for cancer prevention is to halt or delay the genome
instability that leads to somatic genomic evolution and progression to cancer.
1.5. Application of phylogenetic tree estimation or cell lineage reconstruction in
cancer data
Since mitotic cell division results in one cell replicating in two, assuming no horizontal gene
transfer, the cell lineage history of a mitotically dividing cell population must have a
phylogenetic tree structure. Navin et al. recently reviewed the potential of tracing individual
cell lineages in tumors [41]. Also, Navin et al. emphasize the utility of sectioning a primary
tumor into sectors thereby preserving spatial locations of individual sectors, and evaluating
sectors by flow cytometry or by array-CGH for genomic abnormalities in order to infer the
natural history of tumor progression [42]. Salipante and Horwitz review the utility of
capturing genomic variation at genomic sites that have high enough somatic mutation rate in
order to infer the phylogenetic fate of cell lineage [43]. Frumkin et al. and Wasserstrom et al.
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also show that parallel measurements of microsatellites can be used for inferring cell lineages
of cells in various tissues within human or mouse [44,45]. Frumkin e. al. also showed the
feasibility of such approach by typing microsatellites of a mouse tumor and its associated
metastases to reconstruct the temporal order of tumor progression [46]. Both Horwitz and
Shapiro groups develop their own technologies for typing multiple distinct sets of
microsatellites, usually using capillary electrophoresis and robotics for parallelization
throughput. However, those technologies quickly become outdated by SNP genotyping and
next-gen sequencing of entire genomes at ever smaller scales: from micrograms of DNA to
DNA of single cells. A 2012 review from Carlson et al. from Horwitz’s group confirms the
utility of deep sequencing technologies for achieving ever more accurate cell fate maps [47].
One of the first demonstrations of tree estimation was in Louhelainen et al. who typed LOH
at 87 loci of multiple biopsies from multifocal bladder cancers and found that multiple
biopsies appeared to share similar LOH abnormalities thereby suggesting monoclonal origin
as opposed to independent multiclonal origins of those cancers [48]. Ruiz et al. used flow
cytometry, FISH, and PCR to show clonal evolution in a single individual with prostate
adenocarcinoma by analyzing serially sampled (longitudinal) biopsies [49]. Clonal analysis
from 40 pancreatic adenocarcinoma in the same study mapped genomic alterations in
primary and metastatic sites within individuals. The authors concluded that variant clonal
populations can exist within and between biopsies of the same primary tumor and
characterization of the genome and clonal analysis can help manage treatment options and
evaluate the evolutionary response of treatments. However, they did not estimate clonal
relationships using evolutionary methods, such as phylogenetic tree estimation, based on the
shared patterns of DNA content abnormalities and the shared patterns of FISH probe
11

presence and absence. Salk et al. showed that poly-guanine tract (a mononucleotide repeat
microsatellite locus, i.e. a string of “G”s) loci can be useful neutral markers to identify fields
of clonal expansion in patients with ulcerative colitis [50]. Salk et al. used PCR of poly-G
tracts to show that detection of increased clonal expansion increased risk of progression to
colorectal cancer [51]. Tsao et al. sampled mismatch repair deficient (MMR-) colorectal
tumors and measured the length of microsatellite loci with PCR to estimate the mitotic age
of tumors based on a mathematical model of neoplastic progression, based on the
expectation of increased variation in microsatellite length as the tumor undergoes successive
mitoses over time [52]. Campbell et al. detected multiple co-existing subclonal cell
populations within individual patients (n=22 patients total) with B-cell chronic lymphocytic
leukemia using ultra-deep pyrosequencing of the immunoglobulin locus, since rearrangement
at that locus occurs at high frequency, i.e. the somatic mutation rate at that locus is high
making it a useful neutral marker of clonal evolution [53]. In that study, an unrooted
parsimony in PHYLIP was used on sequences that were multiply aligned with
CLUSTALW2. Yachida et al. inferred a pathway series of sequence alterations in pancreatic
adenocarcinoma [54]. All the above studies exemplify the application of evolutionary
approaches to cancer data, i.e. estimation of phylogenetic relatedness among neoplastic
and/or cancer cells.
1.6. Modeling studies of genetic diversity and clonal evolution
The acquisition of somatic genomic abnormalities results in heterogeneous neoplasms and
computer modeling of genomic diversity in neoplasms can help understand plausible
scenarios of how the rates of clonal lineages growth, spread, and mutation affect the overall
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spatial genetic structure of the entire cell population. Chao et al. used agent-based modeling
and experimental skin lesion experimental data and found that the speed of clonal expansion
is driven by death of neighboring cells and appears to follow quadratic rather than
exponential growth [55]. Martens et al., in collaboration with Carlo Maley and myself, used a
2D spatial stochastic Moran model and analytical formulations to show that most parameter
conditions may result in clonal expansions that arise independently at distinct locations
within a neoplasm and come into contact, or interfere, with each other’s expansion, which
results in increased waiting time to cancer [56]. This effect is also termed Hill-Robertson
(clonal) interference. Only small neoplasm size and strong selection will favor periodic
selection over clonal interference. Graham et al. hypothesized three plausible scenarios that
generate the high genetic diversity that is commonly observed in Barrett’s esophagus: high
mutation rate coupled with strong selection, synergizing mutually beneficial interactions
between heterogeneous clones, and an unidentified landscaping alteration driving an initial
clonal expansion on the back of which neutral mutations can hitchhike generating diversity
[57]. Sottoriva et al. developed an agent-based model to explore the generation of epigenetic
methylation patterns during clonal expansions of a growing neoplasm [58]. Nicolas et al.
used crypt methylation patterns, generated by bisulfite treatment and sequencing the BGN
locus on chromosome X, to infer population parameters, such as stem cell number per
crypt, in colorectal cancer [59]. This pioneered the use of approximate Bayesian computation
for inference of parameters by matching summary statistics from observed experimental data
to summary statistics obtained from simulated data. While the above recent advancements in
modeling have illuminated aspects of genetic diversity dynamics, more modeling is needed in
matching models to observations in specific systems, such as Barrett’s esophagus, in order to
13

bound some of the parameter space for explanatory power and for specific predictions for
currently unobservable underlying dynamics.
1.7. Advancements in backward-in-time estimation of the genetic history of a
population
Recent advancements in computing power allowed the application of Kingman’s coalescent
theory (for history of coalescent theory refer to [60]) to genetic data, for estimation of
population genetic parameters. Kuhner et al. developed Bayesian Markov Chain Monte
Carlo (MCMC) methods for estimating population genetic parameters from SNP data [61].
Drummond et al. developed the software BEAST, which is a flexible Bayesian inference
framework for population-genetic parameter inference from serially sampled data [62].
Excoffier et al. developed the software SerialSimCoal, which provides a forward simulation
of population demographics and mutation under various scenarios and parameters,
importantly producing temporally spaced samples [63]. Both BEAST and SerialSimCoal
software programs were, and have been to date, open-source that allowed me to modify
their code and add on novel evolutionary models for novel types of genetic data, such as
data for copy number and LOH abnormalities from SNP array data.
1.8. Chemoprevention in Barrett’s esophagus to prevent progression to esophageal
adenocarcinoma
NSAIDs have a strong and significant effect on reducing the incidence and mortality of
many cancers, including esophageal, colorectal, lung, and other malignancies, [Hazard ratio
was 0.66 (95% CI 0.50-0.87) for all malignancies], however their effect manifests significantly
after more than 5 years of regular use [64]. The majority of epidemiological evidence
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suggests that NSAID use in individuals with BE reduces risk of developing EA [65–68].
Vaughan et al. evaluated 350 individuals followed up for a median of 5.4 years (range 0.2-8.9)
and showed that the 5-year cumulative incidence of EA was 14.3% (95% CI 9.3-21.6 ) for
never users and 6.6% (3.1-13.6) for current NSAID users [67]. The hazard ratio for EA for
NSAID users was 0.20 (95% CI 0.10-0.41) compared with NSAID non-users [67]. Galipeau
et al. showed that NSAID use modulates the risk of developing DNA content abnormalities
(tetraploidy and/or aneuploidy), assayed by flow cytometry, and genetic abnormalities, such
as loss of heterozygosity (LOH) on chromosomes 9p and 17p, assayed by PCR of small
tandem repeat (STR) loci [68]. The benefits of NSAID use for chemoprevention are
attractive due to their widespread use and low toxicity; however the molecular mechanisms
underlying their preventive effect are not fully understood. I evaluate 13 individuals with
Barrett’s in Chapter 4 to show that NSAIDs modulate acquisition of SGA in neoplastic cell
populations.
1.9. Conclusion
In summary, in the next chapters, the population genomic transformation of neoplastic cells
in Barrett’s esophagus would be evaluated in vivo in human over decades of follow-up.
Hopefully, the reader would gain novel insights into the simple central question: “How does
the somatic genome evolve over time in the context of neoplastic evolution and progression
to cancer?”, as I have attempted to best describe qualitatively and quantitatively using novel
technologies for genomic characterization and novel application of methods from
evolutionary biology.
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Chapter 2. Pilot studies evaluating genomic DNA of Barrett’s
esophagus biopsies for somatic genomic abnormalities
2.1. Chapter Introduction
Ever since the sequencing of the human genome [69,70], rapidly emerging commercial
platforms and technologies allowed evaluating the DNA of human tissue specimens for copy
number and loss of heterozygosity abnormalities. At this time, 200 nanograms of DNA
extracted from a human biopsy sample can be evaluated with several commercially available
technologies that have probes to evaluate about 1 to 2 million locations of the 3.2 billion
base pair human genome for about four hundred dollars per sample. Full sequencing of
entire genomes is also available, though the cost is about five thousand dollars per sample
(about a microgram of DNA). Throughout my studies I worked with data from six
platforms for genome-wide DNA assessment: Illumina 33K, Illumina 109K, Illumina 317K,
Illumina 550K, Illumina 1M, and Affymetrix 1M (SNP6.0), single nucleotide polymorphism
(SNP) arrays. I analyzed data from several pilot studies that were designed to evaluate the
capabilities of various technologies to detect accurately and reproducibly DNA copy number
changes and loss of heterozygosity changes in genomic DNA from human tissue specimens.
I collaborated with the Seattle Barrett’s Esophagus Program (SBEP) group to design and
execute several pilot studies to evaluate the Illumina platform, which provided preliminary
evidence for larger scale (case control and case cohort) studies of SGA in biopsies from
individuals with Barrett’s in the SBEP cohort.
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The Illumina SNP platform is based on magnetic bead chips designed to detect single
nucleotide polymorphisms (SNPs) in a human sample. The main application of SNP array
technology has been to call out the major or minor allele (nucleotide variants at a single base
pair position on a chromosome) at each of 33,000 (Illumina Infinium 33K array) to 1
million (Illumina OmniQuad 1M array) positions in the human genome. The design and
manufacturing of a SNP array can influence significantly the quality of results, usually
summarized with two metrics: the signal to noise ratio and the SNP call rate. Gunderson et
al. showed that the advantage of Illumina’s SNP arrays in terms of reducing spatial biases
across arrays is the barcoding of magnetic beads and the random spread of beads on a glass
slide hexagonal lattice during manufacturing and scanning of the barcodes and SNP calling
during single-base pair extension reaction emitting a fluorophore [71]. Peiffer et al. showed
the utility of Illumina SNP arrays for detecting regions of DNA copy number alterations and
loss of heterozygosity [72]. The developments of the Illumina SNP platform increased
density of the probes over time allowing an increased genomic coverage to detect break
points of genomic abnormalities at a higher resolution and to detect small indels.
The SBEP group had evaluated Illumina 33K arrays prior to 2006 and I started a
collaboration with them to evaluate Illumina 109K arrays in 2006, Illumina 317K arrays in
2006-2009, and Affymetrix SNP6.0 and Illumina OmniQuad 1M arrays in 2009-2012. We
performed several pilot experiments, four of which I describe below, to assess somatic
genomic abnormalities (SGA) in Barrett’s biopsies.
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2.2. Pilot experiment evaluating Illumina 109K SNP platform
2.2.1. Introduction and Methods
One of the first pilot experiments we performed was evaluating the signal to noise ratio in
Illumina 109K-SNP arrays. We selected two biopsy samples, two gastric samples, and one
lymphocyte sample from the same BE individual. The lymphocyte sample contains
leukocytes (white blood cells) that contain DNA that represent the germline genotype of the
individual, that is, the DNA lacks any somatic genomic abnormalities. Usually, the DNA
from a gastric biopsy also lacks somatic genomic abnormalities. The aim of the experiment
was to test signal quality difference between two halves of the same biopsy and between two
biopsies from the same patient. The biopsy samples were processed at FHCRC (for full
method description of sample processing refer to Methods in Chapter 4). The final sample
sheet and raw array data were provided to me.
Sample ID

Sample type

Input DNA (ng)

2

Gastric

60

3

Gastric

30

4

BE1

30

5

BE1r (BE1 replicate)

45

6

BE2

30

7

Lymphocyte

150

8

BE2r (BE2 replicate)

75

Table 2.1. Pilot study design for evaluating SGA with Illumina 109K SNP array technology.
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I processed raw SNP array data with Illumina’s BeadStudio software, and wrote Perl
algorithms to detect loss of heterozygosity (LOH) based on genotype calls output from
BeadStudio. I defined a SNP as “LOH-informative” if a SNP is heterozygous (“AB”) in
leukocyte or gastric sample, representing the germline state of the SNP, since such SNPs
would be informative for detecting loss of heterozygosity when such SNPs get an “AA” or
“BB” genotype call in Barrett’s epithelium samples. I developed a Perl algorithm to iterate
trough every SNP along a chromosome and define contiguous regions of LOH (blocks of
LOH), such that contiguous regions contained more than one LOH-informative SNPs.
Also, the algorithm was parameterized to trust the call of a single LOH-informative SNP
(version A) or to trust the call of two contiguous LOH-informative SNPs (version B). In
other words, in version B, if any one of two neighboring LOH-informative SNPs is not
called LOH, then both SNPs get a non-LOH call, which effectively eliminates incorrectly
called singlet SNPs, and increases LOH region calls stringency. In both versions A and B,
two neighboring LOH loci could be separated by LOH-uninformative loci, which are
discarded from consideration. Genotype call concordance was defined as the proportion of
SNPs sharing the same genotype call between two samples, out of a total of 109,365 SNPs.
2.2.2. Results and Discussion
The total number of SNP probes on the 109K SNP platform was 109,365 and when
comparing the genotype calls between samples 2, 3, and 7, there was 99.27% genotype call
agreement among all of the three samples, or only 791 SNPs had discordant calls between
any of the three control samples. This suggests both that it is unlikely that any of these
samples contain a DNA abnormality and that 99.27% of the SNP probes gave out signal
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intensity that after normalization and processing resulted in accurate genotype calls. Also, in
this individual, 35,788 SNPs had a heterozygous “AB” call, thereby labeling 35,788 SNPs as
“LOH-informative” SNPs, and 72,786 SNPs had a homozygous “AA” or “BB” call, thereby
discarding them from LOH analysis. As opposed to apparently normal genotype in samples
2,3, and 7, hereafter referred to as the control samples, multiple somatic genomic
abnormalities were detected in the BE samples.
A total of 719 LOH-informative SNPs showed LOH in any of the samples 4, 5, 6, and 8
when using version A of the LOH detection algorithm. The concordance when comparing
the same biopsy split in half and run on two separate arrays (within biopsy concordance) was
72.11% and 78.28%. The concordance when comparing two biopsies collected from two
different levels from the same endoscopy from the same individual (between biopsy
concordance) ranged from 60.49% to 63.57%.
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n=719

BE1r

BE2

BE2r

BE1

72.11%

63.21%

63.57%

60.49%

62.82%

BE1r

BE2

78.28%

Table 2.2. Genotype call concordance within and between biopsies by trusting genotype calls
of each LOH-informative SNP when detecting contiguous LOH regions. Samples labeled
with “r” are the same biopsy split in half, whereas samples labeled with “1” and “2” are
biopsies collected from two different levels in the Barrett’s segment.

n=272

BE1r

BE2

BE2r

BE1

98.75%

82.89%

82.15%

82.65%

81.25%

BE1r

BE2

96.88%

Table 2.3. Genotype call concordance within and between biopsies by trusting genotype calls
of two neighboring LOH-informative SNPs when detecting LOH regions.

Because of apparently low concordance in SNP calls (Table 2.2) we used version B to call
regions of LOH by trusting the genotype call of two neighboring LOH-informative SNPs
when evaluating LOH event break points. A total of 272 LOH-informative SNPs showed
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LOH in any of the samples 4, 5, 6, and 8 (Table 2.3). The concordance when comparing the
same biopsy split in half and run on two separate arrays (within biopsy concordance) was
98.75% and 96.88% (Table 2.3). The concordance when comparing two biopsies collected
from two different levels from the same endoscopy from the same individual (between
biopsy concordances) ranged from 81.25% to 82.89% (Table 2.3).
2.2.3. Conclusion
The Illumina 109K SNP platform performed well for identifying regions of LOH from
isolated DNA from BE biopsies. The results showed that DNA isolated from lymphocyte
samples and gastric tissue specimens appear normal, that is, lacking any DNA LOH
abnormalities. When biopsies were split in half and evaluated with two separate SNP arrays,
SNPs in regions of LOH showed 72-78% concordance in genotype calls, suggesting very
low between-array variation in signal quality. However, we noticed that the genotype call of a
single SNP cannot be trusted and when we increased stringency by trusting the combined
call of two neighboring LOH-informative SNPs, the concordance in genotype calls increased
to 97-99%, suggesting that bioinformatic methods can improve stringency and accuracy of
LOH calls.
2.3. Pilot experiment evaluating Illumina 317K SNP platform: clonal evolution in one
individual with Barrett’s esophagus over 16 years of follow-up
2.3.1. Introduction and Methods
We designed a longitudinal study of a single individual with Barrett’s esophagus to test
performance of the Illumina 317k platform and to continue developing computational
methods for processing Illumina SNP data. We selected an individual who had been in
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endoscopic surveillance for over 16 years and the morphology diagnosis had been metaplasia
throughout follow-up endoscopic surveillance. We had no specific prior expectation of the
dynamics of somatic genomic abnormalities (SGA) and we only hypothesized that we would
observe accumulation of SGA over time. The aim of this study was to develop
computational methods for handing longitudinal data from BE biopsies from the Illumina
platform and develop methods for estimating phylogenies and estimating population-genetic
metrics, such as rate of acquisition of SGA.
id # date

biopsy Level sample type

ng

1

1989

33

BE

49

2

1989

29

BE

205

3

1989

29

BE

70

4

1993

32

BE

112

5

1993

30

BE

34

6

1993

26

BE

71

7

2001

36

BE

120

8

2001

32

BE

182

9

2001

30

BE

94

10

2006

30

BE

118

11

2006

28

BE

191

12

2006

26

BE

202

13

2006

N/A

blood

104

14

2006

N/A

blood

35

15

2006

43

gastric

200

16

2006

50

gastric

200
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Table 2.4. Sixteen longitudinal samples from the same individual were analyzed with Illumina
317K-SNP arrays. DNA from Barrett’s samples was extracted using epithelial isolation
technique [73] (for detailed sample preparation information see Methods in Chapter 4).
DNA from blood and gastric samples were extracted without the epithelial isolation step.
Biopsies were taken from various time points and various levels from the Barrett’s segment.
Various final amounts of DNA were used on the arrays to compare signal-to-noise ratio
correlation with input DNA amount.
All raw intensity files were loaded in Illumina’s BeadStudio, normalized and clustered using
the SNP manifest and canonical genotype cluster files, provided by Illumina, for build36 of
the human genome. In the following analyses we used the normalized, total signal intensity
“R” for each SNP, which is the sum of the normalized X (“A” allele, Cy5 red) and Y (“B”
allele, Cy3 green) intensities. We also used the B allele frequency (BAF), which is a modified
version of the allelic intensity ratio theta (θ = 2/p*arctan(Y/X)), to reduce SNP-to-SNP
variation in theta using the canonical genotype clusters.
I used Camin-Sokal maximum parsimony reconstruction implemented in PHYLIP [74] to
infer the phylogenetic tree of SGA evolution at loci that showed variation in copy number or
LOH between samples (informative loci).
2.3.2. Results and Discussion
DNA extracted from leukocytes or from a gastric sample represents an unaltered
state of the genome
To detect SGA, a sample representing the normal, unaltered state of the somatic genome is
needed. During an endoscopy, typically a blood sample and a biopsy from the upper part of
the stomach are collected. The gastric biopsy is taken at around ~43-50cm endoscopic depth
from the incisors of the patient, past the gastroesophageal junction (GEJ). I compared all
four samples, samples #13, #14, #15, and #16, against each other and found concordance
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between the signal intensity genome-wide, and no apparent somatic alterations by taking log
ratios between any two samples (data not shown). Ultimately, blood samples are comprised
of red and white blood cells, where only white blood cells (leukocytes) contain DNA. And,
DNA from leukocytes and DNA from gastric epithelium showed no somatic alterations
suggesting that they can be used as control samples when evaluating DNA from epithelium
isolated from biopsies sampled from the Barrett’s segment.

Figure 2.1. Ratio between R of two blood samples and one gastric sample used as reference
samples and the same Barrett’s sample. The signal profiles look similar and fragile site
FRA3B is deleted in the Barrett’s sample and intact in all 3 reference samples. The only
difference between the reference samples is DNA concentration, where samples “blood 1”,
“blood 2”, and “gastric” had 35ng, 104ng, and 200ng of DNA extracted and analyzed with
Illumina 317K SNP arrays. The variation in the amount of DNA used for the genotyping
assay induces a genomic waviness artifact similar to that described in Diskin et al. [75].
I showed that when taking the log ratio between the same BE biopsy and three different
control samples, the same region of copy loss is detected, indicated by a negative log ratio. If
any of the control samples were to have an alteration at the same location, a ratio close to
zero would have been observed instead. Despite variability in signal intensity due to amount
of input DNA was noted, this analysis determined that blood or gastric samples can be used
as normal constitutive genotype control.
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Correlation among GC-content of SNP probes, total signal intensity R from Illumina
SNP arrays, and input DNA amount
As part of initial data quality assessment, I asked whether the %GC-content of SNP probes
(the proportion of the bases G and C in the ~50-mer probe sequence) would affect the
amount of signal intensity they produce. My expectation was that high GC content of a
probe would allow better hybridization between the SNP probe and the sample DNA target
due to three hydrogen bonds between GC as opposed to two between AT. As expected, I
observed a strong correlation between probe GC-content and total normalized signal
intensity R, which is the sum of the red and the green channel for both alleles of a given
SNP (Figure 2.2). Luckily, the actual sequences of SNP probes were not proprietary and
Illumina provided them free of charge, in a manifest file, which allowed this analysis.
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Figure 2.2. Total normalized signal intensity R increases if the SNP probes have higher GCcontent. Shown are all SNPs on chromosome 1 from BE sample #1. The Pearson
correlation between probe %GC and R was 0.57 for these data.
Having tested various input amounts of DNA, I observed that the correlation between
probe %GC-content and total normalized signal intensity R decreased as input DNA
amount increased (Figure 2.3). This suggested that as long as enough DNA is used to
hybridize to the probes, the effect of how many Gs or Cs a probe contains to give a high
signal diminishes. Illumina recommended using 750 ng of DNA for all analyses that use
317K SNP arrays; however, we aimed to minimize the amount of DNA we use per array as
long as it gives enough SGA information in order to save as much biopsy material for
further studies, as technologies advance. These analyses were performed in May 2008 and in
Chapter 4 we used 200ng consistently across all arrays to minimize these effects, although
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200ng would still potentially induce a 0.5 Pearson correlation between probe GC content
and final total normalized signal intensity R.

Figure 2.3. As input DNA amount increases, the correlation between probe GC content and
total signal intensity R decreases. All 12 BE samples had various amounts of input DNA and
at low amounts of input DNA (50ng or below) the signal from the arrays appears noisier and
the effect of probe GC content was stronger. The Pearson correlation was -0.89 for these
data. Note that the Pearson correlation for sample #1 that had 49ng of input DNA is 0.57 as
shown in Figure 2.2.
Analyses of the DNA of samples #1-#12 revealed acquisition of somatic genomic
abnormalities, where the most progressive copy number loss over time occurred at fragile
site FRA3B that contains the gene FHIT (Figure 2.4,
Figure 2.5, and Figure 2.6) and at the genomic location of the tumor suppressor gene
CDKN2A (Figure 2.6, Figure 2.7).
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Figure 2.4. HumanHap300 (317k) array analysis of BE biopsies at the same level (±1cm)
from one patient over 4 endoscopies from 1989 to 2006. In 1989 the BE consensus FRA3B
region showed a region of 1-copy loss (b) flanked by 2-copy loss (a), with an adjacent region
of 1-copy loss (c). In 1993 (a and b) merged into a region of uniform 2-copy loss (f), flanked
by new regions of 2-copy (d) and 1-copy (e) loss. In 2006 the region of 1-copy loss at (c) lost
its second copy (g). Adapted from Lai, Kostadinov, et al. [76].
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Figure 2.5. The same genomic region extended to 61.2 Mb, with a different set of samples
from the same individual show progressive copy loss at various locations within the site.
Adapted from (Brian J Reid, Kostadinov, and Maley 2011).
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Figure 2.6. Benign clonal evolution in 1 patient with Barrett's esophagus studied
longitudinally over 16 years. Purified Barrett's epithelium from endoscopic biopsies was
assayed with Illumina 317K SNP arrays and compared with a blood sample control. A, Copy
number analysis, normalized by SNP intensities from blood, reveals a single copy loss at
CDKN2A in samples 2 (data not shown) and 3 in 1989, but homozygous deletion in
CDKN2A in sample 1 and all samples from subsequent years. At first endoscopy in 1989, 2
clones were detected (1 with a small deletion of 1 allele at the CDKN2A locus, and the other
with copy neutral LOH of the entire 9p arm with the CDKN2A deleted allele, generating
biallelic deletion at CDKN2A). B, the SNP allele frequencies reveal a focal deletion in the
CDKN2A locus in samples 2 and 3 in 1989, but sample 1 included a mixture of the clone
from samples 2 and 3 with a new clone with copy neutral LOH of 9p and biallelic deletion
of CDKN2A. All samples from 1993 and later show that the clone with biallelic deletion of
CDKN2A went to fixation, leading to random noise in the allele frequencies for the SNPs in
that region, as seen in the vertical ("waterfall") band in the bottom panel of B. The fact that
the rest of the 9p arm remains diploid can be seen in the copy number data (A). C, The
clone with deletion of the single allele of CDKN2A, which extends past 22.5 Mb on
chromosome 9p, also had a single deletion in fragile site FRA3B at 60.42 Mb that
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distinguishes it from the other clones. This and other lesions of the clone in samples 2 and 3
were not observed again after 1989, suggesting that this clone was driven to extinction by the
clone from sample 1, with biallelic deletion of CDKN2A. D, A Camin-Sokal maximum
parsimony reconstruction of the genealogy of clones based on the polymorphic copy
number of lesions in 283 loci across the entire genome in the Barrett's biopsies shows that
only one large clonal expansion occurred between 1989 and 1993. After 1993, the Barrett's
segment remained stable, with accumulation of small interstitial lesions but no clonal
expansions, no aneuploidy, and no progression to cancer. Figure adapted from Reid et al. [8].

Figure 2.7. Output from Illumina’s BeadStudio LOHPlus module showing allele frequencies
in 3 samples. A normal sample (top) shows no LOH at p16 (red rectangle). In 1989 a small
deletion of a single allele at p16 has appeared in all samples (middle). By 1993, all samples
have lost both alleles of p16, with the original localized deletion (now apparent by a band of
background readings with random allele frequencies) and loss of the entire arm of 9p in for
other allele.
What is the best statistical measure of a SNP array technology’s performance? The main
purpose of SNP calling has been to associate genetic variants, or SNPs, with disease
covariates, or in other words to detect which SNPs are at high linkage disequilibrium with an
unknown disease marker. To this end, SNP arrays are mainly concerned with accurate calling
of the genotype (the correct base pair) at a given SNP location, and the proportion of SNPs
that have been assigned genotype calls (the “call rate”) has been used as a metric for quality
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control and overall performance of the platform. However, for detecting copy number
abnormalities, the call rate is not as relevant, since the primary aim is to detect regions of
high or low probe fluorescence intensity in test samples in comparison to intensity of control
samples. Therefore, instead of using call rates as metrics of platform performance, I focused
on evaluating the capability of the platform to detect regions of DNA abnormalities and
evaluating the effect of %GC content and input DNA amount on signal quality.
2.3.3. Conclusion
This single case of clonal evolution from longitudinal SGA data provided evidence that
supports the following conclusions: 1) a second clonal expansion had occurred, associated
with a double deletion in CDKN2A, after an initial single clonal expansion, associated with a
single deletion in CDKN2A as well as copy number losses at FHIT; 2) for over ~12 years
since the second clonal expansion, we did not observe a gradual accumulation of appreciable
number of SGAs, except for small scale progressive losses at fragile sites, such as FRA3B; 3)
DNA from leukocyte and gastric samples both showed no SGAs thereby proving being both
useful as paired controls when evaluating SGAs in DNA of BE biopsies; and 4) using the
similar amounts of input amount of DNA on a SNP array can minimize genomic waviness
artifacts.
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2.4. Cross-sectional meta-analysis of copy loss and loss of heterozygosity in Barrett’s
esophagus
Authors: Rumen Kostadinov, Xiaohong Li, Thomas G. Paulson, Patricia C. Galipeau, Brian
J. Reid, Carlo C. Maley
2.4.1. Introduction
Barrett’s Esophagus (BE) is a pre-malignant neoplasm that increases the risk of developing
esophageal adenocarcinoma (EA) [77]. To identify groups of BE patients at high risk of
cancer progression, we sought to identify common chromosomal aberrations across the full
risk spectrum of the condition. I implemented a meta-analysis of three studies from the
Seattle Barrett’s Esophagus Project. The goal of this analysis was to combine SNP and arrayCGH datasets of chromosomal loss from BE and EA samples to pinpoint regions of
common loss across patients.
2.4.2. Methods
The three datasets included Illumina 33k SNP arrays on whole biopsies (34 patients) and
surgical resections specimens (8 patients) from Li et al. [78], an Illumina 317K SNP array on
12 flow purified biopsies (1 patient) from [8] and a 4,500 spot bacterial artificial
chromosome (BAC) hybridization array on 157 flow purified samples (72 patients) from
Paulson et al. [79]. When there were multiple samples from a patient, I included the union of
all detected lesions across those samples but only counted a lesion once per patient for the
purposes of analysis. All SNP arrays were run on both BE and normal (gastric or
lymphocyte) samples from the same patients for comparison. All BAC arrays were run on
BE samples and compared against a common reference sample.
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Illumina’s BeadStudio software was used to call genotypes and produce signal intensity data
in log2 (Rsub/Rref) format that represents the difference in copy number of BE versus normal
samples, where we assume normal samples have no aberrations. I then processed the SNP
data to call regions of copy number loss using GLAD [80] setting logR ratio thresholds of 0.2 for single and -1.5 for double copy loss. BAC data was processed by a wavelet method
[81] to call copy loss, copy gain or no aberration for every BAC. BAC data was analyzed by
Xiaohong Li and the SBEP team and the final copy alteration and LOH data were provided
to me. Regions of copy number loss, for the combination of both SNP and BAC datasets,
were analyzed using STAC [82] to identify statistically significant areas of loss across
samples. The STAC analysis was performed at 0.5Mb resolution using 500 permutations.
2.4.3. Results and Discussion
The combined STAC analysis identified 78 regions that were significant at the 95%
confidence level, after multiple testing correction, including some previously known losses at
chr. 3: 59-61MB (FHIT, FRA3B), chr.16: 77-77.5Mb (WWOX, FRA16D), chr. 9p: 21-32Mb
(p16/CDKN2A/INK4a), and some newly discovered losses at chr. X: 31.5-32Mb (DMD),
chr. 22: 22.5-23Mb (SMARCB1, DERL3, SLC2A11, MIF, GSTT1, GSTT2, DDT, CABIN1,
SUSD2, GGT5) and chr. 18: 57-57.5Mb (CDH20) (Table 2.5, Figure 2.8).
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Table 2.5. Summary of 78 genomic regions that show copy number loss and copy neutral
LOH significantly in common across studies.

Figure 2.8. Example output from STAC from a subset of the 42 individuals that showed
chromosome 9p alterations and analyzed with 33K-SNP arrays and the union of all
alterations from 12 biopsies from one BE individual analyzed with 317K-SNP array. Gray
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bars represent genomic regions on chromosome 9p that are significantly altered across
samples. This plot excludes the BAC array data from 72 patients.
2.4.4. Conclusion
Combining copy number alteration and LOH data across studies in STAC increases sample
size that increases power to detect statistically significant regions of copy number alteration
and LOH across samples. We identified numerous commonly altered regions across
individuals with Barrett’s that could be further investigated for whether individual genes
within those regions are implicated in promotion leading to clonal expansion or progression
leading to esophageal adenocarcinoma.
2.5. Pilot experiment evaluating Affymetrix SNP6.0 and Illumina OmniQuad 1M
SNP platforms
2.5.1. Introduction
The Illumina OmniQuad 1 Million SNPs array technology became available in late 2009
allowing evaluation of 1 million loci of the human genome from approximately 200ng of
human DNA sample at a relatively low cost per array.
2.5.2. Methods
We (SBEP team members, CCM, RK) evaluated both Illumina OmniQuad 1Million-SNPs
and Affymetrix SNP6.0 platforms in preliminary, pilot studies. About 42 DNA samples from
epithelial-isolated BE biopsies were evaluated with Affymetrix SNP6.0 arrays that were run
at the Vanderbilt Microarray Shared Resource (VMSR). A smaller set of DNA samples from
epithelial-isolated BE biopsies were evaluated with Illumina OmniQuad 1M arrays at the
Fred Hutchinson Genomics Facility.
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During an endoscopy, the collected whole biopsies are frequently a mixture of epithelium
and stroma, that is, a mixture of Barrett’s epithelial cells, fibroblast cells, inflammatory cells,
and occasionally normal squamous epithelial cells. The easiest assay to translate to the clinic
is an assay that requires the minimum number of steps from biopsy collection to a readout
of the somatic genomic abnormalities in the biopsy. Therefore, evaluating DNA from whole
biopsies would be easier to translate to the clinic than evaluating DNA from epithelialisolated biopsies. However, only the Barrett’s epithelium typically contains somatic
alterations and other cells present in the biopsy typically have a normal genotype and
evaluating a whole biopsy mixture can reduce detection of SGA in BE cells. We designed a
pilot experiment to compare the SGA detection between whole biopsies and epithelialisolated biopsies. We adapted epithelial isolation method and technique from [73] and
detailed protocol is given in the Methods section of Chapter 5.
SBEP collaborators processed biopsies from 8 BE individuals such that individual biopsies
were split in half and DNA was isolated from whole half-biopsies and from epithelialisolated half-biopsies. Also, DNA from paired blood and gastric samples was also evaluated
for each BE individual to serve as constitutive genotype control. All biopsies were evaluated
with Illumina OmniQuad 1M SNP platform. I compared signal quality and detection of
SGA between 13 “epithelial-isolated versus whole” biopsy pairs.
During this pilot experiment, I developed a MySQL database to store all SNP data and
associated sample information, and developed a pipeline of analysis using the R statistical
language [83] and a browser-based visualization application using
Linux/Apache/MySQL/Perl/PHP/Ajax and Perl-based Circos program by [84]. This set of
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software tools facilitated the development of SGA calling algorithms as well as storage and
visualization of raw and processed SNP data.
2.5.3. Results and discussion

Figure 2.9. dChip-generated raw signal intensity images from two BE samples evaluated with
Affymetrix SNP6.0 at the VMSR facility.
The cross separating the image into four quadrants is composed of copy number variation
(CNV) probes and each quadrant is composed of SNP probes. Every quadrant shows
consistent horizontal light and dark banding patterns. The first image also shows vertical
dark stripes that run through the entire height of the image and that are approximately at
even intervals horizontally. The second image shows a spatial artifact spanning the upper left
and lower left quadrants that could be a manufacturing defect. The first image shows one
dark scratch and one dark point in the lower right quadrant that are also spatial artifacts.
I observed horizontal light or dark banding patterns that were consistent across arrays
(Figure 2.9). Occasionally, there were also horizontal dark lines crossing the extent of the
array vertically (Figure 2.9). I suggested that this consistent variability is due somehow to the
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manufacturing process of the arrays, since Affymetrix arrays are printed using a sequence of
masks, and each SNP probes would always have a predetermined spatial location on the
array. VMSR collaborators suggested that this observed phenomenon would not affect SNP
call rates and that probe redundancy and bioinformatic normalization methods would take
care of the vast majority of the probe intensity variability. However, to the best of my
knowledge, I could find only one study by Wan et al. that addressed these horizontal
banding patterns and designed a normalization method to account for them [85]. Also, SNP
array assays are primarily used for genome-wide association studies, where the call rate (the
proportion of SNP probes on the array that give out a reliable genotype call) is a useful
quality control metric. However, for calling SGAs, call rate is useful only for calling loss of
heterozygosity accurately and the primary quality control metric for calling SGAs is accurate
measurement of total signal intensity across probes.
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Figure 2.10. dChip-generated raw signal intensity image (from the green fluorescence
channel) from four BE samples evaluated with Illumina OmniQuad 1M at the FHCRC
genomic facility.
The image to the left is the actual 100% image that shows the hexagonal nature of the array.
The Illumina arrays also show some spatial artifacts, however due to the random placement
of probes into hexagons on the chip during manufacturing [71], the signal from individual
SNP probes would be random, as opposed to being consitently low or high corresponding
to dark and light horizontal banding patterns from Affy SNP6.
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Figure 2.11. Double copy loss can be detected in an epithelial-isolated half-biopsy and can be
miscalled as single copy loss in its paired whole half-biopsy. Every point represents a single
SNP probe from 20-24 Mb on chromosome 9. On chromosome 9, the tumor suppressor
gene CDKN2A lies between 21.96 and 21.99 Mb and both the epithelial-isolated half-biopsy
(upper panel) and the whole half-biopsy (lower panel) show somatic loss in that
chromosomal region. The log ratio between the epithelial-isolated sample and the blood
control sample was -2.0 or lower, whereas the log ratio between the whole biopsy and the
blood control sample was about -0.5. A two-fold lower signal intensity (log ratio of -2.0 or
lower) in the epithelial-isolated sample would easily be called a double copy (homozygous)
loss by an SGA calling algorithm, however a log ratio of -0.5 in the whole sample would be
easily miscalled as a single copy loss.
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Figure 2.12. Copy neutral LOH can be detected in both epithelial-isolated half-biopsy and its
paired whole half-biopsy. The B allele frequency of both half-biopsies show that the entire
region 20-24 Mb of chromosome 9 has LOH, and since the signal intensity log ratio in
Figure 2.11 hovers around 0, this is indicative of copy neutral LOH. Notably, the epithelialisolated half-biopsy shows a “waterfall” right in the CDKN2A region indicative that the
signal from SNP probes within that region is so low that the scaled difference between the A
allele intensity and the B allele intensity randomly fluctuates between 0 and 1.0.
Evaluation of whole versus epithelial-isolated biopsies using Illumina OmniQuad 1M
showed that probe intensity from whole biopsies was affected because of the mixture with
normal genotype cells and as result some SGAs would be missed (

Figure 2.11 and Figure 2.12). The detection of a “waterfall” pattern in B allele frequency
(Figure 2.12) suggests that the BE epithelial-isolated sample is primarily composed of BE
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epithelial cells and lacking any contaminating normal cells. If there was a significant
contamination from cells or DNA having normal constitutive genotype a three cluster
pattern, representing the AA, BB, and AB normal genotypes, would be observed instead of a
“waterfall” pattern. This three cluster pattern is faintly visible in the whole half-biopsy in the
CDKN2A region on chromosome 9 (lower panel of Figure 2.12).
2.5.4. Conclusion
Overall, same samples run on both platforms showed concordance in final SGA calls, which
is also supported by a study by Curtis et.al. [86]. However, my assessment suggests that Affy
arrays may suffer from consistent spatial biases in signal intensity requiring additional
bioinformatic normalization steps, whereas Illumina may provide better initial signal
intensity potentially requiring fewer bioinformatic normalization steps. Also, we had existing
pipelines and expertise in handling and processing data with custom algorithms and software
from the Illumina platform, which also influenced the choice of platform. The final choice
of platform and facility was Illumina and FHCRC genomic facility, which had the advantage
of having comparable cost for sample processing and the advantage of closer collaboration
on DNA quantitation issues. Consequently, Illumina OmniQuad 1M was used for the largescale experiment in Chapter 4. The final choice of biopsy processing method was to use
epithelial isolation since using whole biopsies attenuated signal and resulted in missing or
incorrect SGA calls.
2.6. Chapter summary
These four pilot experiments using Illumina and Affymetrix SNP array platforms helped
provide enough preliminary evidence for accurate evaluation of SGA in BE biopsies and
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preliminary evidence for having a robust set of software tools to process SNP data and
visualize results. The pilot experiment with 317K arrays on a single individual showed an
initial clonal expansion, and a second clonal expansion, but an apparent evolutionary stasis
of SGA after the second clonal expansion over the last 12 of a total of 16 years of clonal
evolution. The pilot experiments comparing Affymetrix and Illumina 1M-SNP arrays
suggested that both platforms performed approximately equally. The experiments also
suggested that using epithelial isolation yields better signal compared to using a whole
biopsy, which contains stroma in addition to Barrett’s epithelium. All of the results served as
preliminary evidence in winning a grant from the American Cancer Society that allowed us
to perform a larger study of clonal evolution in 13 individuals and 161 biopsies using the
Illumina 1M-SNP platform (Chapter 4).
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3.1. Abstract
Background
Esophageal adenocarcinoma (EA) is a disease of the somatic genome, the etiology of which
relies on evolution by natural selection of somatic cells. In EA’s precursor condition
Barrett’s esophagus (BE), increased genetic diversity at baseline detection is associated with
increased risk of progression to EA. Clonal expansions have been observed in BE and have
been thought to play a role in neoplastic progression. However, little is known whether and
how clonal expansions affect genetic diversity dynamics, where dynamics is the change in the
level of genetic diversity in a Barrett’s cell population over time. Specifically, under what
conditions can clonal expansions induce decreases in genetic diversity over time?
Methods & Findings
We assessed plausible scenarios for genetic diversity dynamics in BE with forward-in-time
simulations of the change in genetic constitution of BE crypt populations over time. Initially,
a BE segment was initialized with a genetically homogeneous population of crypts that fill
out a hexagonal 2D lattice. During each simulation crypts mutate, replicate, die, and expand
in neighboring hexes according to mutation rate, replication rate, death rate, and neighbor
interaction parameters, respectively, based on their initially normal but subsequently mutated
genotypes. Additionally, a duration of 20 years from initiation to EA and five rate-limiting
mutations to EA were assumed per simulation run. We found that in less than 6% of
parameter value combinations, genetic diversity decreased by more than 1% at any time
during simulation runs. Decreases in genetic diversity are also magnified when we make the
assumption that crypt mutation rate is independent of crypt replication rate as opposed to
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proportional to it. We also found that neighbor interaction was one of the most important
parameters for determining the speed of progression, i.e. whether or not a crypt must wait
for a neighbor crypt to die before it can divide into the emptied space.
Conclusions
These modeling findings suggest that genetic diversity most likely increases monotonically
over time despite clonal expansions. Therefore, we predict that monotonic increases in
genetic diversity over time would be observed in vivo in most individuals with BE.
3.2. Introduction
Esophageal adenocarcinoma is a disease of the somatic genome, the etiology of which relies
on evolution by natural selection of somatic cells. Although heterogeneity in premalignant
conditions and cancer has been recognized, genetic diversity as measured in the fields of
ecology and evolutionary biology has not been widely applied to cancer diagnosis and
treatment. Little is known how genetic diversity within neoplasms changes over time, where
competing hypotheses suggest that genetic diversity may either increase monotonically over
time or decrease periodically during clonal expansions (see Figure 2 in [27]). Computational
modeling can be used to understand genetic diversity as one fundamental aspect of
progression to cancer in hope of advancing a conceptual understanding of progression,
which may guide the design of future therapies to interrupt progression.
Although genetic heterogeneity is increasingly recognized as being a useful metric of
neoplastic progression [31,87], to date, only a limited set of studies have highlighted an
association of genetic diversity with clinical features of neoplasms. Barrett’s esophagus is a
unique pre-malignant human condition, in which the dynamics of genetic diversity can be
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studied over time in vivo. This is possible since current clinical practices recommend
enrollment of individuals with BE in endoscopic surveillance programs, which collect and
store biopsies from Barrett’s tissue over time [5]. Maley et al. and Merlo et al. found that
multiple measures of clonal genetic diversity in biopsies, collected at initial (baseline)
detection of Barrett’s, predict progression to EA [88,89]. Genetic diversity has also been
measured in other cancer types. Park et al. characterized diversity in 15 human breast tumors,
which were diverse mixtures of ductal carcinoma in situ and invasive regions, and found that
genetic diversity, measured using Shannon’s index, was associated with clinically relevant
variables, such as tumor grade [33]. If genetic diversity in neoplasms is associated with
clinically relevant variables, understanding how the level of genetic diversity changes over
time may help in estimating the timing of manifestation of clinically relevant features, or in
other words, in measuring the onset of clinical stages of carcinogenesis.
Clonal expansions characterize the growth of clonal cell populations, yet few studies have
shown that measurements of clonal expansions can predict progression of a pre-malignant
condition to cancer. Galipeau et al. observed clonal expansions in 61 individuals with BE by
measuring loss of heterozygosity at microsatellite loci on chromosomes 9p and 17p, where
some expansions had covered the entire BE segment [90]. Based on these data, Galipeau et
al. hypothesized that clones bearing genomic abnormalities such as LOH can arise
independently or bifurcate over time, which generates observed clonal heterogeneity within
BE segments [90]. Leedham et al. found heterogeneity at individual crypt level where crypts
within microdissected blocks showed similar LOH and point mutation patterns, and crypts
from spatially distant blocks showed distinct LOH and point mutation patterns, suggesting
local clonal expansions and a degree of clonal intermingling [34]. Graham et al.
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hypothesized that the generation and maintenance of genetic diversity in Barrett’s is
explained by 1) strong mutation and strong selection, 2) group selection, where diverse
clones as a group are selected, and 3) an hidden initial landscaping genetic abnormality
triggering clonal expansion on which neutral mutations occur and generate diversity [57].
Clonal expansions have been measured in pre-malignant ulcerative colitis, which can
progress to colorectal cancer. Salk et al. measured the lengths of polyguanine microsatellites
in biopsies collected from 2D patches of pre-malignant tissue in patients with ulcerative
colitis and found that clonal expansions inferred by shared microsatellite length patterns
were associated with progression to colorectal cancer [51]. Salk et al. further hypothesized
that clonal expansions measured with any neutral markers could be useful for predicting
neoplastic progression [50].
The interplay of genetic diversity and clonal expansions is complex. Genetic diversity is an
outcome of the underlying evolutionary parameters of neoplastic cell populations, including
mutation, selection, clonal expansion, and spatial structure. Martens et al. explored the effect
of spatial structure on the waiting time to cancer and found that under most biologically
realistic parameter values clones tend to arise independently and come in contact as they
expand, slowing dynamics and reducing the time to cancer, as opposed to arising sequentially
after clonal fixation, which leads to quicker progression to cancer [56]. Mutation rates have
only been indirectly estimated from cancer age-incidence data in a few cancers, such as
colorectal cancer [91], (never in Barrett’s esophagus) and the number of clonal expansions
involved in neoplastic progression have been estimated from 2 in lung cancer [92] to 20 in
colorectal cancer [93] (there are no formal estimates in Barrett’s esophagus). Here we explore
how mutation rate and spatial structure parameters affect clonal expansion and genetic
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diversity by assuming a fixed fitness landscape with 5 fitness-increasing rate-limiting
mutations that underlie at least 5 clonal expansions.
Also, we model “selective” (driver) and “neutral” (passenger) genetic abnormalities that
represent any category of mutation, such as point mutations, copy number alterations, loss
of heterozygosity, and structural rearrangements. Abnormalities at selective loci result in
advancing tumor progression through the stages of carcinogenesis, and have a fitness
increasing effect. Abnormalities at neutral loci confer no fitness benefit; however it is neutral
loci that define the observed mutation states when sampling tumors, or in other words,
neutral loci are observed variables that are dependent on the hidden (latent) variables of the
underlying evolutionary parameters, such as mutation rates and fitness landscape defined by
the fitness-modulating selective loci.
What are the dynamics, or change in magnitude, of genetic diversity over time? Our prior
hypothesis is that in the absence of clonal expansions genetic diversity is a monotonically
increasing function of time as new somatic genomic abnormalities (SGA) accumulate in the
neoplastic cell population. However, we aim to explore the plausibility of decreases in
genetic diversity during periods of clonal expansions that may homogenize the genetic
constitution of the population. The population genetic diversity may be a monotonically
increasing function of time, which can be modeled with linear, exponential, logarithmic, and
other mathematical growth functions. However, the population genetic diversity may instead
oscillate over time, for instance, it may increase as SGA accumulate but decrease during
periods of clonal expansions, making genetic diversity harder to model, as Merlo et al.
proposed [27].
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Figure 3.1. Plausible scenarios for genetic diversity dynamics. Genetic diversity can decrease
periodically due to clonal expansions; for instance, if five necessary, sufficient, and ratelimiting steps (mutations) are acquired sequentially in the neoplastic cell population and
boost fitness enough to cause five clonal expansions, they may homogenize the neoplasm
and produce five troughs in genetic diversity (solid line). Such oscillating dynamics can be
captured only with longitudinal data so that troughs in genetic diversity can be detected.
Alternatively, genetic diversity can increase monotonically over time and modeled as a linear
function of time (dashed line). Alternative hypotheses, such as a single genetic catastrophe or
a critical phase transition point, can also be plausible, in this example, reduced to a simple
sigmoid curve (dotted line). Importantly, at time of detection of a new tumor, measurement
of genetic diversity and prior knowledge of the typical dynamics of genetic diversity taken
together can estimate the time elapsed since tumor initiation and predict the waiting time for
tumor progression to cancer. Elapsed time since initiation and waiting time to cancer are
clinically relevant variables for diagnostic purposes and for weighing treatment options.
3.3. Methods
We fix a set of parameters at the beginning of each simulation
. The Barrett’s segment is represented as a two
dimensional

(height

width) hexagonal lattice, wrapped around along the

dimension to form a cylinder. At the beginning of the simulation, all

hexes are

occupied by crypts having no mutations. Crypts have an initial birth rate (number of crypt
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fission events per day), and when dividing, one of its daughter crypts remains in its original
hex (self-renews) and the other daughter crypt either expands into an empty neighboring hex
or, if none exist, kills off a neighboring crypt and occupies its hex space with probability .
Intuitively,

describes the stochastic neighbor contact process, where for

, replicating

crypts crowd out and replace their neighbor crypts, instead of waiting for an empty hex as
when

. Crypts have an initial death rate

(number of death events per day), where

upon dying, the crypt’s hex is emptied.
The mutation states of crypts are stored in matrix , that has
columns, where
survival) and

rows (crypts) and

is the number of selective loci (modulating crypt reproduction and

is the number of neutral loci (having no effect on crypt reproduction or

survival). Taking both neutral and selective mutations together, there are l = m+n total
possible loci at which mutations may occur.

At the beginning of each simulation, all
neutral locus

, and during the run, every mutation hitting a
sets

, to count multiple hits at

neutral loci, whereas every mutation hitting a selective locus

sets

, which

makes selective loci irreversible, that is, when mutated they stay mutated for the duration of
the run, whereas neutral loci can record the number of changes, which can be useful for
representing microsatellite shifts, or single base pair substitutions.
Selective loci are stored in vectors

and

, and each locus

must have either reproductive selection coefficient satisfying
or survival selection coefficient satisfying

,
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otherwise

and

make the locus neutral. Thus, loci having

or

are

selectively advantageous (increase birth rate and decrease death rate, respectively) and loci
having

or

are selectively deleterious (decrease birth rate and increase death rate,

respectively).
As crypts acquire mutations in selective and neutral loci over time, their birth, death, and
mutation rates are calculated as follows:
Equation 1:

The birth rate
advantage

of crypt is the initial crypt birth rate multiplied by the reproductive

conferred from any mutated

selective locus .

Equation 2:

Similarly, the death rate
survival advantage
positive value for

of crypt is the initial rate of crypt death

conferred from any mutated

multiplied by the

selective locus . Note that a

lowers the death rate, whereas a positive value for

increases birth

rate.
We allow neutral loci and selective loci to have distinct rates of mutation
depending on the assay modeled, neutral loci

, since,

could represent somatic copy number

polymorphisms, microsatellite or methylation sites, that have higher mutation rates
. Other genetic alterations, such as point mutations and structural
rearrangements could also be modeled with different mutation rates, but we have focused on
alterations with relatively high mutation rates that are more likely to be used for quantifying
54

within neoplasm diversity. However, those alterations are modeled in the selective loci
which represent the loci that will acquire the ~3-5 rate-limiting mutations necessary for
initiation and promotion of epithelial cancers. Those rate-limiting steps (driver mutations)
are thought to have relatively low mutation rates

.

Equation 3:

Equation 4:

Equations 3 and 4 give the mutation rate at selective loci

and neutral loci

for crypt .

One of two mutation models is fixed at the beginning of each simulation: time-dependent
or replication-dependent

. In the time-dependent model, the crypt mutation

rate is not affected by changes in crypt division rate: setting the term
in Eqs. 3 and 4, whereas in the replication-dependent model, mutations modulating the crypt
division rate, also modulate mutation rate using the term

. Intuitively, the

replication-dependent model means that crypts that divide faster will also mutate faster,
reflecting more (cell-intrinsic error-prone DNA) replication of stem cells in dividing crypts,
whereas the time-dependent model means that regardless of faster or slower crypt division,
mutations are time homogeneous, as might occur with on-going stem cell replication in nondividing crypts, as well as chronic DNA damage from acid reflux, inflammation, or other
cell-extrinsic causes.
Thus far, equations 1-4 describe the four actions that a crypt executes with four distinct
rates: division, death, mutation of a selective locus chosen at random, and mutation of a
neutral locus chosen at random. Having a population of

crypts, each having four rates
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and distinct mutation states, presents a computational challenge for efficient forward-in-time
stochastic simulation. We address that by using a Gillespie algorithm that can be summarized
in three steps: choosing the first action to execute from an exponential distribution with rate
equal to the sum of all action rates of the population of crypts, advancing time according to
that action, and choosing the appropriate individual crypt that performs the action. When a
crypt divides in space, its genotype must be copied to the new location, which is
computationally intensive for a single simulation of ~0.1-1 billion crypt divisions. We
address that by having hex locations point to crypts stored in a large phylogenetic tree in
memory that records exact divergence times and mutation differences among clonal
populations of crypts, resulting in average run times of ~5 minutes per run on Core i7-975
3.3 GHz, using ~3 GB of RAM.

Equation 5:
We ran 360 simulations that represent all combinations of initial parameters in the fixed
initial value column of Table 3.1. We also ran an additional 120 simulations (All parameter
sweeps in Table 3.1, except that neutral mutation rate was fixed to 10 -4) to evaluate genetic
diversity dynamics in a fully-mixed crypt population scenario, in which crypts divide into six
randomly chosen hex locations in the grid according to the same rules as dividing into six
neighbor hex locations: first, if any of the six locations are empty, divide into a randomly
chosen empty hex, and second, if all of the six locations are occupied, replace a crypt with
probability p. The state of the hexagonal 2D lattice was output at half-year intervals during
each simulation run. The estimate of genetic diversity

(kappa) was computed by sampling
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crypts ( = 100) from random hex locations without replacement from the

segment

and summing the hamming distance between mutation states over all neutral loci
for all

pairwise crypt comparisons (Equation 5). We ran a

peak and trough detection algorithm to find local minima and maxima of the resulting curve
of genetic diversity over time.
In this simulation, individual crypts occupy positions in a hexagonal grid. They have base
rates of birth and death which can be modified by mutations at selected loci. Two key
parameters of this system are whether crypts can kill their neighbors in order to reproduce or
must wait for an empty space, and whether the rate of mutation is proportional to time or to
crypts divisions (so that faster-dividing crypts, assumed to be driven by faster dividing stem
cells, accumulate more mutations). Non-selected (neutral) loci are also modeled so that the
simulation can be compared to genome-wide samples from Barrett’s Esophagus.
Parameter

Description

Units

Fixed initial
value

Does
parameter
value
change
during
simulation
run?

Range during
simulation run

h

grid height

number of
hex cells

300

no

N/A

w

grid width

number of
hex cells

300

no

N/A

p

neighbor hex
cell
replacement
probability

[0,1]

{0,.25,.5,.75,1}

no

N/A

t

simulation

days

0

yes

[0,7300]
57

run time
b

crypt birth
rate

number of
crypt
fission
events per
day

0.02

yes

[0.005,1]

d

crypt death
rate

number of
crypt death
events per
day

0.016

yes

[0.005,0.1]

a

timedependent
mutation
model (a=0)

{0,1}

{0,1}

no

N/A

replicationdependent
mutation
model (a=1)
n

number of
neutral loci

number of
neutral loci

100

no

N/A

m

number of
selective loci

number of
selective
loci

10

no

N/A

μ

crypt
mutation rate
of selective
loci

number of
mutations
per locus
per crypt
birth

{10-6, 10-7,
10-8}

no

N/A

v

crypt
mutation rate
of neutral loci

number of
mutations
per locus
per crypt
birth

{10-4, 10-5,
10-6, 10-7}

no

N/A

r

vector of
reproduction
selective
advantage

{[0,∞),…,
[0,∞)}

{.6,.8,1,1.2,1.4,
0,0,0,0,0}

no

N/A
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multipliers
s

vector of
survival
selective
advantage
multipliers

{[0,∞),…,
[0,∞)}

{0,0,0,0,0,
.6,.8,1,1.2,1.4}

no

N/A

X

Matrix of
mutation
states at
neutral and
selective loci
(columns) of
all crypts
(rows)

For each
selective
locus 1..m
the state is
{0,1}
For each
neutral
locus
m+1..m+n
the state is
[0..∞)

0

yes

X[*,1..m]
ranges {0,1}
X[*,m+1..m+n]
ranges [0..∞)

Table 3.1. Parameter configurations for forward-in-time simulation of evolutionary dynamics
in Barrett’s Esophagus.
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3.4. Results

Figure 3.2. A spatially-structured crypt population induces monotonic increase in genetic
diversity. Genetic diversity is computed by taking a random sample of 100 individual crypts
from the grid. The neutral mutation for the displayed parameter sweeps is 10-4. Black lines
represent crypt division-dependent mutation (a=1) and red lines represent time-dependent
mutation (a=0). Each parameter sweep was run in triplicate.
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Figure 3.3. A fully-mixed crypt population induces periodic decreases in genetic diversity.
Genetic diversity is computed by taking a random sample of 100 individual crypts from the
grid. The neutral mutation for the displayed parameter sweeps is 10-4. Black lines represent
crypt division-dependent mutation (a=1) and red lines represent time-dependent mutation
(a=0). Each parameter sweep was run in triplicate.
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Figure 3.4. Biopsy sampling (n=12) for a fully-mixed crypt population, where biopsy size
was 10x10 crypts and mutation detection threshold was 0%.
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Figure 3.5. Biopsy sampling (n=12) for a fully-mixed crypt population, where biopsy size is
10x10 crypts and mutation detection threshold is 5%. The neutral mutation for the displayed
parameter sweeps is 10-4. Black lines represent crypt division-dependent mutation (a=1) and
red lines represent time-dependent mutation (a=0). Each parameter sweep is run in
triplicate.

Figure 3.6. Example grid spatial dynamics from year 5-20 (7 panels left to right), when
selective mutation rate is 10-6 and neutral mutation rate is 10-4. A fully-mixed crypt
population has quicker genetic diversity dynamics than a spatially-structured crypt
population. The grid state over time is displayed in colors, where crypts are colored by the
genetic similarity based on neutral mutation patterns (principal components analysis reducing
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100 neutral loci to three red, green, and blue dimensions, first row) and by the number of
selective mutations they have acquired (magenta to red, second row). Clones expand locally
driven by acquisition of fitness-increasing SGAs and neutral SGA hitchhike on the clonal
expansions forming complex patterns according to crypts’ phylogenetic histories.
We found that genetic diversity increased monotonically in 339 out of 360 simulation runs
and decreased by ≥ 1% at any time during the remaining 21 simulation runs. We estimated
“biopsy-based” genetic diversity over time by sampling 12 biopsies at random locations
without replacement and successfully detecting mutations at neutral loci that are at ≥ 0% or
≥ 5% frequency in the population of 100 crypts comprising a biopsy in Figure 3.4 and
Figure 3.5, respectively. We estimated “individual-crypt-based” genetic diversity over time
by sampling 100 individual crypts without replacement at random locations within the grid in
simulations with spatially-structured crypt population (Figure 3.2) and in simulations with
fully-mixed crypt population (Figure 3.3).
3.5. Discussion
We assumed that neoplastic cell population in Barrett's esophagus is organized into a
hexagonal 2D lattice and clones bearing acquired somatic genomic abnormalities (SGA)
expand by crypt fission. The crypt cycle model was originally proposed by Totafurno et al.
[94] and expansion of mutations by crypt fission was experimentally confirmed by Greaves
et al. [95,96]. We hypothesized that BE crypts are not in a steady state, but are continuously
cycling, given the observation of branching crypts in histopathology slides of biopsies
sampled throughout segments [97]. In addition, we hypothesized that SGAs that occur in the
self-renewing stem cell population at the bottom of crypts can expand spatially through
successive cycles of crypt replication. This hypothesis is supported by evidence that the same
mitochondrial DNA point mutations were found present in both arms of colon crypts
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undergoing fission, as well as in patches of neighboring crypts, thus establishing crypt fission
as the mechanism for the spread of mutations in crypt-structured human colonic epithelium
[95]. We assumed a population of 90,000 crypts in a typical Barrett's segment, which is not
dramatically different from a mean 72,480 crypts per segment estimated from 13 individuals
in Barrett’s (Chapter 4, Supplementary table S1). Empirical evidence suggests that over the
duration of endoscopic surveillance the Barrett's segment length remains constant over time
(see Figure 1.2 in Chapter 1), therefore we held constant the width and height of the
Barrett’s segment during a simulation run.
In BE, typically a maximum of twelve biopsies are collected per endoscopic procedure, or
time point during follow-up visit. We found that the underlying genetic diversity, which we
estimated by comparing 100 individual crypts from random locations, was underestimated by
this standard biopsy sampling protocol. This could be overcome if individual crypts are
sampled from available biopsies.
Neoplastic cell populations can acquire SGAs, which can be produced by single catastrophic
events, chromothripsis [98], or genomic firestorms [99], as well as a variety of other
mechanisms including repair of double strand breaks by homologous recombination [100].
Some SGAs may increase neoplastic cell fitness resulting in clonal expansion that changes
the frequencies of neutral and selective SGAs within and outside of the expanding clone
(Figure 3.6). These changes in frequency modulate the level of genetic diversity and periodic
measurements of genetic diversity provide a snapshot of evolutionary dynamics in the
neoplasm.
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The agent-based model we developed can be used to simulate a vast number of evolutionary
scenarios and to calculate a vast number of summary statistics, such as number and sizes of
clonal expansions and genetic diversity dynamics. The model allows the input of a userdefined fitness landscape by specifying the exact number of fitness-modulating loci and their
associated fitness-modulating values. The model has a quick run-time and records a
phylogenetic tree of the evolution of clonal crypt lineages and outputs complete information
of the mutational state of the grid with associated statistics of clone sizes, parent
relationships among clones, and fitnesses (replication rate and death rate) of clones. All of
those capabilities allow the comparison of summary statistics of simulated data to
experimentally-obtained data from individual Barrett’s segments in future studies.
Approximate Bayesian computation methods can assess distance between summary statistics
of simulated and real data to estimate the underlying set of evolutionary dynamics parameter
values, such as mutation rates, crypt expansion parameters, and number of fitnessmodulating loci and their associated fitness modulating effects. Our model is an
advancement in modeling evolutionary dynamics in its increased complexity by
parameterizing genomic states of driver and passenger loci, fitness landscapes of driver loci,
and by recording individual run phylogenies.
3.6. Conclusion
In summary, our findings suggest that genetic diversity most likely increases monotonically
over time despite clonal expansions; and we predict that monotonic increases in genetic
diversity over time would be observed in vivo in most individuals with BE. In such
monotonic increase scenarios, measurements of genetic diversity at regular intervals can be
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used to estimate the elapsed time since initiation of Barrett’s esophagus and to estimate the
waiting time to progression to esophageal adenocarcinoma. The underlying genetic diversity
is likely to be better estimated when genotyping individual crypts from biopsies as opposed
to evaluating a mixture of crypts under most population parameter settings.
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4.1. Abstract
Background
Cancer is considered an outcome of decades-long clonal evolution fueled by acquisition of
somatic genomic abnormalities (SGAs). Non-steroidal anti-inflammatory drugs (NSAIDs)
have been shown to reduce cancer risk, including risk of progression from Barrett’s
esophagus (BE) to esophageal adenocarcinoma (EA). However, the cancer chemopreventive
mechanisms of NSAIDs are not fully understood. We hypothesized that NSAIDs modulate
clonal evolution by reducing SGA acquisition rate.
Methods and Findings
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We evaluated 13 individuals with BE. Eleven had not used NSAIDs for 6.2±3.5
(mean±standard deviation) years and then began using NSAIDs for 5.6±2.7 years, whereas
two had used NSAIDs for 3.3±1.4 years and then discontinued use for 7.9±0.7 years. 161
BE biopsies , collected at 5-8 time points over 6.4-19 years, were analyzed using 1MillionSNP arrays to detect SGAs.
We observed a significant increase in the acquisition of new SGAs off-NSAIDs compared to
on-NSAIDs (60±166 vs. 28±48 per biopsy, p=0.013) and in pre-existing SGAs that dropped
out of detection on-NSAIDs as compared to off-NSAIDs (92±143 vs. 19±21 per biopsy,
p<0.01). The estimated SGA rate was 7.8 per genome per year (95% support interval [SI],
7.1–8.6) off-NSAIDs and 0.6 (95% SI 0.3–1.5) on-NSAIDs. Twelve individuals did not
progress to EA. In 10 we detected 279±86 SGAs affecting 53±30 Mb of the genome per
biopsy per time point and in two we detected 1,463±375 SGAs affecting 180±100 M b. In
one individual who progressed to EA we detected a clone having 2,291±78 SGAs affecting
588±18 Mb of the genome at three time points in the last 3 of 11.4 years of follow -up.
Conclusions
NSAIDs were associated with reduced rate of acquisition of SGAs. The BE cell population
maintained relative evolutionary stasis over prolonged periods in most individuals but
occasionally stasis was punctuated by expansion of clones having massive amount of SGAs.
4.2. Introduction
Clonal evolution is a theory that explains the phenomenon of the progressive morphological
and genetic change of somatic cell populations from normal homeostatic cell division and
death within tissues to abnormal neoplastic growth and cancerous spatial expansion within
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and across tissues [2,27,101]. Clonal evolution is the Darwinian evolution by natural
selection of asexually (mitotically) dividing somatic cells. Somatic genomic abnormalities
(SGA), such as copy number alterations and loss of heterozygosity (LOH), can be used as
polymorphic DNA markers for identifying evolving clones. Strictly defined, a clone is a
genetically identical subpopulation of cells within the cell population of a tissue, that
descends from a most recent common ancestor (MRCA) cell and therefore all of the clone’s
cells inherit the SGAs that were originally present in the MRCA cell. However, a commonly
used, relaxed definition of a clone is descent with modification from a MRCA cell, which
allows for accumulation of additional SGA heterogeneity among the cells of the clone. In
other words, a clone ideally represents the shared cell lineage history of a subpopulation of
cells. The acquisition of SGA variability (SGA polymorphism) over the course of cell
division allows for classification of cell subpopulations into clones. In the remainder of this
study, we use clone in its relaxed definition and we estimate phylogenetic trees from acquired
SGA variability to qualitatively describe relatedness among evolving clones. The generation
of new clones is stochastic and the change in clones’ frequencies in the population is
determined by clones’ relative fitnesses. New adaptive and new neutral clones can arise
stochastically over time [102] with every newly acquired SGA that does or does not affect
fitness, respectively (Figure 1A,B). In order to prevent progression to cancer, mechanisms
that modulate clonal evolution by either preventing SGA acquisition or preventing the
spread of SGA-containing clones need to be elucidated.
Barrett’s esophagus (BE) is a condition of the distal esophagus in which the normal stratified
squamous epithelium is replaced by columnar epithelium with intestinal metaplasia [5]. BE is
thought to develop as a complication of chronic gastroesophageal reflux disease (GERD),
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and individuals with BE are at increased risk of progression to esophageal adenocarcinoma
(EA): 1-7 persons with BE progress to EA per 1000 person-years [6,7]. Strategies for early
detection and prevention of esophageal adenocarcinoma have focused on all aspects of the
GERD-BE-EA sequence: acid suppression medications, anti-reflux surgery, esophagectomy,
ablation of premalignant Barrett’s esophagus, endoscopic biopsy surveillance of Barrett’s
esophagus, and chemoprevention using aspirin or other non-steroidal anti-inflammatory
drugs (NSAIDs) [5,103]. Barrett’s esophagus is a pre-malignant condition in which clonal
evolution can be studied in vivo, since a standard of care is periodic endoscopic surveillance
with concomitant biopsy, providing a tissue bank that facilitates studies of clonal
evolutionary dynamics over time.
Genomic instability is a common feature of solid cancers [2,29,36,38,104]. In a recent study,
Beroukhim et al. evaluated 3131 cancer specimens from 26 histologic types and 1480 normal
tissue specimens and found that copy number gains and losses affected 17% and 16% of the
genome in a typical cancer specimen and only 0.35% and 0.1% of the genome in a typical
normal tissue specimen [35]. Despite the recent massive accumulation of data on genomic
alterations in cancers from the Cancer Genome Atlas and the International Cancer Genome
Consortium initiatives, theoretical modeling of the generative process (clonal evolution)
producing the observed SGA patterns and underlying neoplastic progression has remained
limited [27,101]. BE is associated with genomic instability and acquired SGA [76,78,79,105]
allowing analysis of the acquisition of SGA over time. This provides data for estimating SGA
acquisition rate that is a key parameter of clonal evolution.
NSAID use significantly reduces the incidence and mortality rates of many types of cancer,
including esophageal adenocarcinoma [64–68,106]. Rothwell et al. showed that the hazard
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ratio for cancer incidence of NSAID users vs. NSAID non-users was 0.66 (95% CI 0.500.87); however a robust NSAID cancer preventive effect manifests significantly only after
≥5 years of regular use [64]. The majority of epidemiological studies in BE suggest that
NSAID use in individuals with BE reduces risk of developing EA [65–67,106]. Specifically,
Vaughan et al. evaluated 350 individuals followed up for a median of 5.4 years (range 0.2-8.9)
and showed that the 5-year cumulative incidence of EA was 14.3% (95% CI 9.3-21.6 ) for
NSAID never users compared to 6.6% (3.1-13.6) for current NSAID users and that the
hazard ratio for EA incidence of NSAID users vs. NSAID non-users was 0.20 (95% CI
0.10-0.41) [67]. Galipeau et al. showed that NSAID use reduced the 10-year cumulative
incidence of esophageal adenocarcinoma from 79% to 30% in individuals with Barrett’s
esophagus who had one or more somatic genomic abnormalities detected at baseline
endoscopy, which included DNA content tetraploidy and/or aneuploidy, assayed by DNA
content flow cytometry, or genetic abnormalities, such as loss of heterozygosity (LOH) on
chromosomes 9p and 17p, assayed by PCR of small tandem repeat (STR) loci [68]. NSAID
use for chemoprevention is attractive due to the widespread use and low toxicity and side
effects of that class of drugs; however the molecular mechanisms underlying the NSAID
cancer preventive effect are not fully understood. In this study, our aim was to evaluate the
effect of NSAIDs on the accumulation of somatic genomic abnormalities by evaluating the
entire genome (1 Million SNP loci) for SGA. We hypothesized that NSAID use modulates
clonal evolution by reducing the prevalence of SGA by either reducing the incidence of SGA
over time (SGA rate: number of SGAs acquired per genome per year) or interfering with the
expansion of clones bearing newly acquired SGAs over time (Figure 1A,B).

73

To test this hypothesis, we used a prospective observational crossover study design: a
longitudinal study in which the sequence of NSAID use was recorded for each individual
during the follow-up period. We selected thirteen individuals with BE from our cohort, who
had endoscopic follow-up of mean 11.8 ± 3 years (range: 6.4–19) and who began or
discontinued NSAID use exactly once during follow-up. All thirteen individuals had to have
at least two consecutive time points (≥6 biopsies) off NSAIDs and at least two consecutive
time points (an additional ≥6 biopsies) on NSAIDs. To estimate SGA prevalence in biopsies
on and off NSAIDs we used summary statistics of observed patterns of SGA; to estimate
SGA rates on and off NSAIDs we used an evolutionary analysis of observed SGA patterns
to take into account SGA phylogenetic identity by descent. Drummond et al. showed that
mutation rates can be estimated from longitudinal samples in virus populations using
coalescent and phylogenetic methods within a Bayesian Markov Chain Monte Carlo
framework for sampling model parameter space (BEAST package, Bayesian Evolutionary
Analysis Sampling Trees) [62,107]. We adapted BEAST to estimate SGA acquisition rates on
and off NSAIDs. Thus, the crossover study design provided 13 independent tests of the
hypothesis of NSAID-associated reduction in SGA acquisition rate since every individual
had both on and off NSAID periods and SGA acquisition during those periods.
4.3. Results
We evaluated the dynamics of detected SGAs over time. The mean number of SGAs and the
proportion of the genome they affected remained approximately constant over time, for as
many as 19 years (e.g., Figure 4.2, individual a). Individuals b, f, and j, shown in red in Figure
4.2A and Figure 4.2B, showed much greater variation in detected SGA over time, compared
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to the rest of the individuals, shown in black. Progression to EA was not part of our study
inclusion criteria, and individual j was the only individual who progressed. Individual f did
not progress to EA, but rather opted for esophagectomy for high-grade dysplasia after 6.4
years of follow-up and subsequently died of a different cancer 11.9 years later. In individuals
b,f, and j, the mean (± standard deviation) number of SGAs per genome per time point was
1,082 ± 177 , 1,844 ± 573, and 1,154 ± 746 respectively, and the amount of genome affected
by SGAs was 119 ± 79 Mb, 242 ± 121 Mb, and 227 ± 222 Mb, respectively. In the rest of
the individuals, the mean number of SGAs per genome per time point was 279 ± 86 and the
amount of genome affected was 53 ± 30 Mb. Assuming a human genome length of 3,164
Mb (Human genome GCRh37.p5 assembly), individuals b, f, and j had 3.8 ± 2.5%, 7.6 ±
3.8%, and 7.2 ± 7% altered somatic genome per time point, compared to 1.7 ± 0.9% altered
somatic genome in the rest of the individuals. Figure 4.2 suggests an overall evolutionary
stasis in this sample of persons with BE, i.e., in most individuals, contrary to expectations,
we did not observe a gradual increase of SGA over time.
The unexpected result of long-term evolutionary stasis suggested that the effect of NSAIDs
on reducing SGA rate would be challenging to detect. We evaluated newly-appearing SGAs
during periods of NSAID use and NSAID non-use by excluding all SGAs that were detected
at baseline. Baseline SGAs were excluded since they had occurred and increased in frequency
for an unknown amount of time prior to detection at baseline and since we have selfreported NSAID use information reaching back only 6 months prior to baseline. Across all
individuals, we detected 28 ± 48 newly appearing SGAs per biopsy during on-NSAID
periods (n=73 biopsies) compared to 60 ± 166 newly appearing SGAs per biopsy during offNSAID periods (n=57 biopsies), which was a significant difference (Wilcoxon test,
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p=0.013). We also evaluated whether NSAID use is associated with regression of preexisting SGAs (dropping out of detection), by evaluating only SGAs that are detected at
baseline, or during NSAID use or non-use periods, but not detected in the last endoscopy. A
significantly greater number of existing SGA events dropped out of detection on-NSAIDs,
as compared to off-NSAIDs (92 ± 143 [n=55] vs. 19 ± 21 [n=79], Wilcoxon test, p<0.01).
In summary, NSAID use was associated with a reduced number of newly appearing SGAs of
any size (Figure 4.3A) and with higher number of pre-existing SGAs of any size dropping
out of detection (Figure 4.3B).
While the natural history of clonal evolution was different in each individual, some common
patterns can be discerned. The majority of SGAs are present in the first time point, with
little accumulation of SGAs afterwards (Figure 4.6). This can also be seen in the radial
spokes apparent in the Circos plots that summarize SGAs across the whole genome at each
time point (Figure 4.4B, Figure 4.4C, Figure 4.5B, Figure 4.5C, and Supplementary Figure
4.7), that represent the most common lesions in BE [76,78], on chromosomes 9p
(CDKN2A), 3p (FHIT) and 16p (WWOX). We found no evidence of selective sweeps of
clones throughout the Barrett’s segment in any of our 13 patients over at total of 153
patient-years. This can be seen in the consensus trees generated by BEAST (Figures Figure
4.4D, Figure 4.4G, Figure 4.5D, Figure 4.5G, and Supplementary Figure 4.8). These
genealogies show that multiple clones appear to co-exist over the entire period of follow -up.
Even in the one patient who progressed to EA, individual j, the clone with massive SGAs
(2,291 ± 78 SGAs affecting 588 ± 18 Mb or 19% of the genome in biopsies 8,10,11, and 13)
remained localized (Figure 4.4). Interestingly, a precursor of that clone had been detected 9
years prior to its emergence (biopsy 2 in Figure 4.4G,H,I). We show clonal evolution in
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individuals b, j, and f in higher detail in figures 4 and 5 since these individuals had a higher
than average number of SGA events and amount of genome altered (Figure 4.2). We show
clonal evolution in individual l (Figure 4.5) in higher detail to show clonal evolution during
an on-off NSAID use pattern. In addition, the SGA amount in individual l is close to the
mean SGA amount in all individuals, except b,f, and j, while SGA amount in individual f is
higher than the mean (Figure 4.2) and using Circos plots side-by-side contrasts qualitatively
SGA amount and SGA chromosomal location between individuals l and f (Figure 4.5 B,C).
In summary, the majority of patients showed little gradual accumulation of new SGAs
consistent with long-term evolutionary stasis during follow-up (Circos plots in Figure 4.4,
Figure 4.5 and Supplementary Figure 4.7), and the one progressor to EA, individual j,
showed that evolutionary stasis can be punctuated by the expansion of a clone with massive
amount of SGAs (Figure 4.4 C,G,H,I).
The maximum-parsimony phylogenetic analysis revealed the shared common ancestry of
biopsies within an individual based on SGA homology. Inferred PAUP* phylogenetic trees,
which had branches scaled by the estimated number of shared SGA events in Figure 4.4E,H,
Figure 4.5E,H, and Supplementary Figure 4.9, showed significantly imbalanced tree shapes
(Supplementary Table 4.3) for all individuals, except individual f and j. When we rescaled the
branch lengths of the same phylogenetic trees by the amount of genome affected in Figure
4.4F,I, Figure 4.5F,I, and Supplementary Figure 4.9, the trees showed that within an
individual the majority of biopsies cluster together and only few biopsies or lineages shoot
out of the majority cluster, which is indicative of SGA bursts.
We tested our hypothesis that NSAID use reduces SGA acquisition rate in Barrett’s
esophagus by estimating SGA acquisition rate during off-NSAID and on-NSAID periods
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using a custom modified version of BEAST. We added a new evolutionary model of SGA
into BEAST in order to estimate SGA rate using Bayesian MCMC sampling (see Methods
and Equations S3,4). We excluded SGAs detected in the first time point and only measured
SGAs that were detected during follow-up, in order to reduce the influence of clonal
evolution that occurred prior to surveillance. For the two individuals who were already on
NSAIDs when we started surveying them, and later went off NSAIDs, individual l showed a
lower SGA rate on NSAIDs than off NSAIDs, but the 95% support intervals for the two
rates overlap (Figure 4.6). In contrast, individual m showed a higher SGA rate on NSAIDs
than off NSAIDs. In individuals a-k, the SGA rate on NSAIDs was approximately an order
of magnitude lower than the SGA rate off NSAIDs, with non-overlapping 95% support
intervals (Figure 4.6), which is consistent with the hypothesis that NSAID use reduces SGA
acquisition rate (on average 7.8 SGAs per genome per year off-NSAID vs. on average 0.6
SGAs per genome per year on-NSAID in individuals a-k).
4.4. Discussion
Somatic genomic abnormalities inevitably occur in a population of asexually (mitotically)
dividing somatic cells, and if such SGA affect cell fitness, the cell population will evolve by
natural selection and may evolve neoplastic and cancerous overgrowth. It is virtually
unknown how clonal evolution unfolds in a human neoplasm over time since long-term
observation is not feasible in the majority of benign and malignant conditions. However, in
this longitudinal study of the premalignant condition Barrett’s esophagus, we were able to
evaluate the evolutionary dynamics of SGA in neoplasms of 13 individuals over more than a
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decade of follow-up, in 5-8 time points, and estimate the effect of NSAID use on
modulating SGA dynamics.
We observed long-term evolutionary stasis, detecting an approximately unchanging mean
number of SGAs across multiple biopsies and across multiple time points over an average of
11.6 years of follow-up (Figure 4.2). The estimated SGA rate on-NSAID and off-NSAID
was 0.6 and 7.8 SGAs per genome per year, respectively (Figure 4.6). Few newly-appearing
SGAs were observed during follow-up, either off-NSAID or on-NSAID periods (Figure
4.3A, Supplementary Figure 4.12). The maximum-parsimony phylogenetic analyses show
tree topologies consistent with gradual accumulation of SGA events on the leading-edge of a
clone, possibly during initiation that results in an imbalanced tree shape (Figure 4.4E, H,
Figure 4.5E, H, and Supplementary Figure 4.9 and Supplementary Table 4.3). However,
when inferred SGA events were converted to amount of genome they affected, the branch
lengths (x-axis) of trees show little gradual accumulation of SGA amount (Figure 4.4F,I,
Figure 4.5F,I, and Supplementary Figure 4.10) consistent with relative evolutionary stasis.
These two results suggest that the accumulation of SGA events only affected a tiny fraction
of the genome. The observation of long-term evolutionary stasis is consistent with a
hypothesis that BE can function as a benign and perhaps protective evolutionary adaptation
of epithelial tissue to duodenal gastroesophageal reflux [8]. According to that hypothesis, the
multilayer squamous population of cells at the distal end of the esophagus encounters a new,
acidic microenvironment when the development of a hiatal hernia, often associated with BE,
permits chronic exposure to reflux. Constitutive germline variants (evolution at the
population level) can synergize with acquired somatic genomic abnormalities (evolution at
the somatic tissue level) to modulate the propensity for developing BE that appears to be a
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successful adaptation of the tissue in response to exposure to reflux [8]. In addition, the BE
epithelium may have a survival advantage over the native multilayer squamous because it is a
columnar secretory epithelium that expresses mucosal defense functions, such as bicarbonate
secretion [16], mucus secretion by goblet and other columnar cells [18], expression of
claudin-18 tight junctions [23], and overexpression of genes involved in defense and repair
[15,24,108,109]. The observation of evolutionary long-term stasis at the genome level is also
consistent with the hypothesis that the BE is a benign condition that rarely progresses to
EA, corroborated by epidemiological evidence that only 1-7 persons with BE progress to
EA per 1000 person-years [6,7].
However, apparent evolutionary stasis at the level of analyses of biopsies may miss ongoing
accumulation of SGAs within single crypts. If those clones never grow larger than a few
crypts, they would not be detected by our assays. Further work will be necessary to
determine if the stasis seen at the biopsy level is a result of the lack of accumulation of SGAs
in crypts or the lack of clonal expansions of those SGAs to detectable sizes. Our selection
criteria, both for patients that have used NSAIDs, and for at least 5 time points over at least
6.4 years of follow-up may have led to selection bias for individuals with relative
evolutionary stasis in their Barrett’s epithelium.
While evolutionary stasis dominated the dynamics of SGA over time, NSAID use was
associated with detectable reduction in the rate of acquisition of SGA. NSAID use reduced
SGA rate from an average of 7.8 SGAs per genome per year off-NSAID to 0.6 SGAs per
genome per year on-NSAID (Figure 4.6). NSAID use was also associated with reduction in
the number of newly appearing SGAs and increase in the number of pre-existing SGAs
dropping out of detection (Figure 4.3, Supplementary Figure 4.12). These results suggest that
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a possible underlying mechanism of the NSAID effect on reducing cancer risk may be
modulating SGA evolution by reducing the acquisition of new SGA, inhibition of spread of
SGA-containing clones, preventing massive bursts of SGA, and possibly induction of
apoptosis in clones having high numbers of pre-existing SGAs.
Evolutionary stasis can be punctuated by a massive catastrophic burst of SGA. Individual j
was the only individual who progressed to EA and the only one that showed the sudden
appearance of a clone with massive SGA affecting 19% of the genome, yet that clone
remained stable for ~3 years prior to EA occurrence (Figure 4.4 A,C,G,H,I). Interestingly,
biopsy 2, taken at the baseline endoscopy 8.5 years prior to detecting the clone with
massively altered genome, shared a subset of the SGAs with that clone (chromosomes 10,
12, 17 and 18), and thus biopsy 2 is likely to be an early, ancestral progenitor of the massively
altered clone. This one observation illustrates the need for larger studies to identify altered
states of the genome, early in progression, that may prime the genome for future bursts of
massive alterations. We hypothesize four possible mechanisms for a long-term dynamic of
stasis interrupted by a massive burst and followed again by stasis: 1) small SGAs or point
mutations that we miss by our assay may accumulate and hit key genes involved in DNA
maintenance and repair, leading to a massive catastrophic event that disrupts the genome, 2)
massive bursts of SGA occur often, but in most cases bursts have deleterious consequences
on cell fitness and those clones do not survive, 3) epistatic interactions among multiple loci
in the genome exist in such configuration that makes acquisition of SGAs at any one of the
loci deleterious, but simultaneous acquisition of SGAs at multiple loci beneficial and 4)
SGAs gradually accumulate within a small region of the Barrett’s segment, potentially as
small as a single crypt, that we miss in biopsy sampling until they eventually expand. The first
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hypothesis might be supported or ruled out with more detailed data using next-generation
sequencing. However, it may not be likely since we did not detect apparent continued
accumulation of SGAs over time in individual j; if DNA maintenance or repair mechanisms
were inactivated we would expect a linear or exponential increase in the amount of SGA
after the burst. It is also possible that SGA continued to accumulate in cells descended from
the original burst, but these subclones did not expand to detectability, so these mutations
were not visible in our assay. The second hypothesis may be likely given the rare observation
of biopsies having a burst in SGA, for example biopsy 5 in individual b (Figure 4.4 A,B,D,F).
The third hypothesis can only be supported or ruled out by a cross-sectional study with
hundreds of between- and within- individual samples that might reveal a signature of cooccurring SGAs. The fourth hypothesis can be evaluated by analyses of the SGA
heterogeneity among individual crypts within a biopsy and analyses of the relationship
between spatial distance and genetic distance among biopsies and crypts within the Barrett’s
segment. These four hypotheses are not mutually exclusive and may instead synergize to
generate the observed stasis-punctuation-stasis evolutionary dynamic. Interestingly, the
relative stasis observed after the massive SGA punctuation event is consistent with the
observation of a relatively stable aneuploid population of cells detected in a primary breast
tumor and its associated liver metastasis [110]. Moreover, the pattern of massive SGA
(Figure 4.4C) may have been generated by a multipolar mitosis [29] or a sequence of bridgefusion-breakage cycles and could be classified as chromosomal instability, “chromothripsis”,
“complex genomic firestorm”, or genetic catastrophe types of SGA patterns that have been
observed in other solid tumors [35,36,38,98,99,110].

82

4.5. Methods
Human Subjects
Participants were selected from the Seattle Barrett’s Esophagus Study, a research cohort
founded in 1983. Surveillance endoscopies were performed and biopsies were taken using a
standardized four quadrant sampling protocol [111]. At endoscopy, anatomical landmarks
including the gastroesophageal junction (GEJ) and ora serrata (OS) were noted, which define
the lower (distal) and upper (proximal) boundaries, respectively, of the Barrett’s segment.
During an endoscopy, biopsies were taken every one or two cm along the length of the
Barrett’s segment. At each level, four biopsies were taken approximately at 0°, 90°, 180°, and
270° around the circumference of the esophagus for histologic evaluation. Endoscopic
biopsies for molecular studies were collected in Minimal Essential Media (MEM) with 10%
DMSO (Sigma #D-5879), 5% heat inactivated fetal calf serum, 5mM Hepes buffer on ice
and frozen at -70°C. In 1995 the research protocol added an epidemiologic interview in
which individuals were questioned about NSAID use, as previously described [67]. In
addition, the protocol added blood collection at the time of endoscopy for use as a control,
since blood DNA represents putatively unaltered germline genotype.
Study design
Individuals were selected in the cohort who had at least a 3cm-long BE segment at baseline.
Individuals were further selected based on NSAID use status changing exactly once during
prospective follow-up and based on having at least two endoscopic procedures while using
NSAIDs and at least two while not using NSAIDs. At least five years of follow -up was also
required in order to observe evolution over time. Thirteen individuals met these inclusion
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criteria (Figure 4.1C). The history of NSAID use at each endoscopy was evaluated with a
questionnaire that was also used in a US collaborative case-control study of esophageal
adenocarcinoma [112]. As part of the questionnaire, individuals are shown cards (i.e., typed
lists of drugs with trade names and generic names) to facilitate recall. Individuals were also
asked about indications for taking NSAIDs, and reasons for stopping in those who were no
longer regular users. The criterion for regular NSAID use at an endoscopy was taking an
NSAID at least once per week for the last 6 months. Regular NSAID use over multiple
endoscopies defines a time interval on-NSAIDs and absence of NSAID use over multiple
endoscopies defines a time interval off-NSAIDs. We approximated the transition point
between NSAID use and non-use by taking the middle time point equidistant between the
two endoscopies when the NSAID use changed (Figure 4.1C, white-gray boundary). Eleven
individuals (a-k) were not on NSAIDs at the start of surveillance and then went on NSAIDs
(had an “off–on NSAIDs” pattern during surveillance), and two individuals (l,m) had the
opposite, starting surveillance on NSAIDs and then stopping their use (an “on–off
NSAIDs” pattern). The median follow-up surveillance time per individual was 11.6 years
(range 6.3-19). A total of 74 endoscopies and 161 biopsies were selected as well as one blood
sample for each of the thirteen individuals to serve as normal constitutive genotype control.
Sample preparation
The 161 frozen biopsies were thawed and rinsed in Hanks buffered salt solution without
divalent cations (HBSS, Gibco/BRL). Biopsies were incubated 60 minutes at room
temperature in 30mM EDTA in HBSS preheated to 37°C. Barrett's epithelium was isolated
by gently peeling it away from the stroma with microdissection needles under a dissecting
microscope [73]. The 13 frozen blood samples were processed the same way as the biopsies,
84

except for the epithelial isolation step. DNA was extracted using Puregene DNA Isolation
Kit as recommended by the manufacturer (Gentra Systems, Inc. Minneapolis, MN). Samples
were quantitated using the Picogreen method (Quant-iT dsDNA Assay, Invitrogen). A total
of 200ng of DNA at 50ng/ul concentration was analyzed using Illumina Omni-Quad 1M
SNP arrays according to manufacturer’s protocol. All samples were evaluated at the Fred
Hutchinson Cancer Research Center Genomics Core Laboratory.
GenomeStudio processing
All raw intensity files were loaded in Illumina’s GenomeStudio v3, normalized and clustered
using the SNP manifest and cluster files for build37 of the human genome. In all our
analyses we used the total signal intensity R for each SNP, which is the sum of the
normalized X (“A” allele, Cy5 red) and Y(“B” allele, Cy3 green) intensities. We also used the
B allele frequency (BAF), which is a modified version of the allelic intensity ratio theta (θ =
2/p*arctan(Y/X)), to reduce SNP-to-SNP variation in theta using the canonical clusters.
GLAD segmentation
Each individual’s BE DNA samples were paired to the individual’s control sample (DNA
from blood from the same individual), which always appeared normal, i.e. lacking any
chromosomal alterations (none of the control samples had any split in BAF over the entire
genome, data not shown). For each individual, we first excluded the 0.2% of SNPs with the
lowest R values in the control sample, to remove SNP probes that either perform poorly or
fall within germline copy number variant (CNV) regions. We corrected for dye bias (higher
fluorescence of the B allele, Cy3 green) by re-centering the BAF of heterozygous and
homozygous SNPs of all samples from observing that the median BAF of heterozygous
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SNPs was ~0.53, instead of 0.5. Then, for each individual, we identified the set of
heterozygous SNPs; i.e., SNPs having a BAF in control sample between 0.33 and 0.66.
Finally, we separated the data into three signal profiles: log 2 (R of BE sample / R of control
sample) for heterozygous SNPs only, log 2 (R of BE sample / R of reference) for
homozygous SNPs only, and reflected and scaled BAF of BE sample, (mBAF= abs(BAF of
BE sample – 0.5)*2) for heterozygous (informative for LOH) SNPs only. We performed
separate wavelet-based segmentation on these three signal profiles using the HaarSeg
algorithm [113] from the GLAD [80] package (using parameters haarStart=3, haarEnd=9,
fdrQ=0.0001, onlySmoothing=T).
SGA detection
For each biopsy sample, we combined all break points of the segmented three signal profiles
to create a new set of segments that is the union of the segments from the three signal
profiles unique to each individual’s biopsy. For every new segment, we used thresholds to
call allelic imbalance based on the smoothed mBAF profile, and to call single or double copy
gain or loss, based on the homozygous and heterozygous log 2R profiles. Thus every new
segment meeting the thresholds received one of eight molecular state calls: AB (normal), AA
(copy neutral LOH), A (single copy loss), 0 (double copy loss), AAB (single copy gain), AAA
(LOH plus subsequent single copy gain), AAAA (LOH plus subsequent double copy gain),
AABB (double copy gain). In summary, Supplementary Table 4.2 shows all calling
thresholds used and supplementary figures showing raw data segmentation and SGA calls
for all 161 biopsies of individuals a-m.
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The GLAD segmentation detects break points of SGA for each sample individually. For
each individual, we combined all break points across the individual’s samples and ran a
segment merging procedure that merged two adjacent, neighboring segments if they had the
same molecular state call across all samples of that participant. Thus, the number of
segments per individual can vary. IMPUTE2 [114] and a reference dataset of 566 CEU
haplotypes, part of the 1000 Genomes Project [115], was used to phase each individual’s
blood control sample. Having haplotype assignments for the A and B alleles of every SNP,
we developed an algorithm to assign a haplotype state for every segment of allelic imbalance.
This results in conversion of AA, A, AAB, AAA, AAAA calls to BB, B, BBA, BBB, BBBB
calls for segments having lost or gained the opposite allele. For simplicity of all subsequent
analyses, all segments having AB molecular states were assigned an “absence of SGA” call,
and all segments having other molecular states were assigned a “presence of SGA” call. The
final results are individual-specific phylogenetic matrices having samples as taxa,
chromosomal segments as characters, and binary molecular states (SGA absence/presence,
or 0/1) as character states.
Phylogenetic analyses
To measure mutation rate change associated with NSAID use, we used a two epoch model
in BEAST [107], where the transition time between the first and second sampling periods is
the time of change in NSAID use. We ran BEAST for 10 million Bayesian MCMC iterations
that sample the space of genealogies and population parameters to obtain posterior
distributions for model parameters that best fit the data. We used uniform prior distributions
for SGA rate with lower and upper bounds of 10 -5 and 104 SGAs per biopsy genome per
year, respectively, for the duration of any of the on-NSAID and off-NSAID periods and
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estimated SGA rate separately for the first and second sampling periods, where each SGA
rate adheres to the molecular clock hypothesis (SGA occur at constant rate for all evolving
lineages) for the period duration. We added a 0/1 mutation model in BEAST for the SGA
absence/presence character states (see Equations S3-4) and this model assumed that SGAs
do not revert to the normal type, i.e., 1→0 transition is impossible. We also modified
BEAST’s likelihood calculation algorithm to consider a last universal common ancestor
(LUCA) that has an unaltered genomic state (zeros for all sites), and that connects to the
most recent common ancestor (MRCA), at the root of the tree, creating an extra LUCAMRCA branch. Thus, the final likelihood of the tree is the product of the likelihood of the
tree at the root, calculated with Felsenstein’s pruning algorithm [116], multiplied by the
probability of the LUCA-MRCA branch length. Maximum parsimony trees were estimated
using Wagner parsimony with delayed transformation (DELTRAN) on the individualspecific phylogenetic matrix with 0/1 SGA states using the PAUP* program [117]. For
PAUP* analyses, we also used a character transition matrix that assumes infinite cost for
1→0 transitions, i.e. SGAs do not revert to normal type.
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4.6. Figures

Figure 4.1. Hypothesis and study design for evaluating the NSAID effect on clonal evolution
in Barrett’s esophagus (BE). (Panels A, B) BE is a condition in which the normal stratified
squamous epithelium (white) of the distal esophagus is replaced by specialized intestinal
metaplasia (colors). During endoscopic surveillance (0-20 years, x-axis), the anatomical
landmarks gastroesophageal junction (GEJ) and “ora serrata” (OS) define the lower (distal)
and upper (proximal) boundaries of the Barrett’s segment (y-axis), respectively. The mean
distance between GEJ and OS is 5 cm in our cohort, and typically remains constant in size
throughout 0-20 years of follow-up time. While the origin and initiation of BE is debated, we
followed the model of Wang et al. where BE is thought to arise at GEJ from a residual
embryonic population [118]. This initiation model is also consistent with observations of a
columnar, secretory epithelium that forms superficial esophageal glands before being
displaced by stratified squamous epithelium during embryonic development [119]. We
estimated that the mean length of the initiation period in BE is 5.81 years by measuring crypt
density and fraction of branching crypts and assuming a single progenitor crypt and logistic
population growth of crypts by crypt fission (Supplementary Table 4.1). Somatic genomic
abnormalities (SGA) that confer a selective advantage give rise to clones that increase in
frequency in the neoplasm over time (adaptive SGAs, yellow to blue colors). SGA that are
selectively neutral give rise to clones that fluctuate in frequency in the neoplasm over time by
genetic drift (neutral SGAs, gray). (Panel A) In the absence of NSAID use, clonal evolution
is fueled by acquisition of SGA. Chromosomal instability (red unstable clone) can lead to
increased clonal genetic diversity and progression to cancer. (Panel B) We hypothesized that
long-term NSAID use lowers the rate of SGA acquisition. (Panel C) To test this hypothesis,
we evaluated 13 individuals with BE, eleven of whom were not using NSAIDs (offNSAIDs) for 6.2 ± 3.5 years (mean ± standard deviation) and then began using NSAIDs for
5.6 ± 2.7 years, and two of whom were using NSAIDs for 3.3 ± 1.4 years and then
discontinued use for 7.9 ± 0.7 years. Frozen biopsies were assayed from 5–8 endoscopies
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from each individual, marked with x’s. The DNA from 161 BE biopsies and 13 blood
samples was analyzed using 1M SNP arrays to detect SGA.

Figure 4.2. The mean number of detected somatic genomic abnormalities (SGA) and the
amount of the genome they affect remain approximately constant over time in Barrett’s
esophagus. (Panel A) Solid lines connect the means at each time point for all individuals (am), where the symbols a-m are plotted at the end of the lines. The mean number of SGAs
per biopsy-genome per time point was 1,082 ± 177, 1,844 ± 573, and 1,154 ± 746 (mean ±
standard deviation) in individuals b, f, and j, respectively, compared to 279 ± 86 in the rest
of the individuals. In this instance, number of SGAs is an individual-specific estimate of the
total number of independently acquired SGA events and is computed by counting the
number of abnormal genomic segments identified by the union set of all detected SGA
break points across samples of a given individual (See GLAD segmentation and SGA detection in
Methods). (Panel B) The mean amount of genome affected by SGA per time point was 119
± 79 Mb, 242 ± 121 Mb, and 227 ± 222 Mb for individuals b, f, and j, and 53 ± 30 Mb for
the rest of the individuals.
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Figure 4.3. The effect of NSAIDs on appearance and regression of SGA events. (Panel A)
NSAID use is associated with appearance of fewer new SGA events. For this analysis, we
excluded all SGAs present at baseline because they had occurred and increased in frequency
for an unknown amount of time prior to detection at baseline and since we have selfreported NSAID use information reaching back only 6 months prior to baseline. We
counted only new SGAs that appeared within the off-NSAID or on-NSAID periods. (Panel
B) NSAID use is associated with a decrease in detectable cell populations with pre-existing
SGAs. For this analysis, we restricted the analysis to only the SGAs not detected in the final
endoscopy in order to count their regression during either the on-NSAIDs or off-NSAIDs
periods. (Panels A, B) We binned newly appearing or regressed pre-existing SGA according
to lesion size (0 bp–100Mb, x-axis), but detected no apparent effect of NSAID use on
selection for or against lesions of a specific size category; rather, NSAID use affected all size
categories of SGAs equally. (Wilcoxon rank-sum test, 2-sided p-values, *** p<0.01, **
p<0.05, * p<0.1, solid bars and associated error bars represent mean and standard deviation
of newly appearing and regressing SGAs per biopsy).
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Figure 4.4. Clonal evolution in individuals b and j. (Panel A) Solid lines connect the mean
amount of SGA detected across biopsies at each time point. Dots correspond to biopsies
taken during follow-up (x-axis) that have total SGA detected by SNP arrays (y-axis). In
individual b (black line), we observed evolutionary stasis, where the mean amount of SGA
was 119 ± 79 Mb over more than a decade of follow -up. In individual j (red line), we
observed evolutionary stasis up to year 7, which was disrupted by a massive burst of SGA
detected in year 8.5. Three years after the appearance of this massively altered clone,
individual j progressed to esophageal adenocarcinoma. Individual b started NSAIDs after
year 5, while individual j started regular NSAIDs use only after year 10. (Panels B and C)
Genome-wide view of SGA over time in individuals b and j. Each ring, labeled with a biopsy
number, represents whole-genome SGA data from a different biopsy. Thin black line rings
separate endoscopies (time points), white background shows time periods off-NSAIDs and
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gray background shows time periods on-NSAIDs. Within the rings, black segments
designate homozygous deletion, red single copy loss, orange copy-neutral LOH, and green
shows copy gain. (Panel B) Circos plot of SGA in individual b. Note the appearance of
“new” whole chromosome LOH at chromosome 6 and 11 in biopsy 5, taken during the offNSAIDs period, and the detection of a clone lacking alterations on chromosomes 4, 12, 17
and 20, in biopsies 9 and 7, taken during the on-NSAIDs period. (Panel C) Circos plot of
SGA in individual j. A massive burst of SGAs was detected first in biopsy 8, in year 8.5,
before the individual began regular NSAID use. Biopsy 2 (second inner ring), taken at the
baseline endoscopy 8.5 years prior to the burst, shared a subset of the SGAs seen in the
massively altered clone (chromosomes 10, 12, 17 and 18), and thus is likely to be an early,
ancestral progenitor of the massively altered clone. (Panels D and G) Consensus
phylogenetic trees estimated by BEAST reveal long-term co-existence of clones. Branch
lengths are scaled according to time, the tips of the phylogeny are biopsies aligned on the xaxis according to their sampling time, and all internal nodes are estimated coalescence times
assuming a logistic population growth model (see Methods and Text S1). Dashed gray line
represents the onset of NSAID use. In participant j, we detected 1,215 SGAs affecting 211
Mb of the genome in biopsy 2, the likely progenitor clone that presaged the appearance of
2,357 SGAs affecting 578 Mb of the genome in biopsy 8, 8.5 years later. In participant b,
biopsies 7–10 have few SGAs and only a small amount of genome affected by SGA. (Panels
E, F, H, I) Maximum parsimony trees estimated by PAUP reveal the ancestral relationships
among biopsies based on shared SGA characters. Branch lengths are scaled according to
estimated number of SGAs (Panels E, H) or the amount of genome affected by SGA (Panels
F, I).
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Figure 4.5. Clonal evolution in participants l and f. (Panel A) In individual l (black), the mean
amount of SGA was 54 ± 29 Mb over time, whereas in individual f (red) the mean amount
of SGA was 242 ± 121 Mb over time. (Panels B and C) Genome-wide view of SGA over
time in individuals l and f. (Panel B) During the off-NSAID period in individual l, we
detected a whole-chromosome gain of chromosome 8 in biopsy 12 (green band) and some
copy-neutral LOH events on chromosome 1 in biopsies 9 and 11 (orange bands). (Panel C)
We detected 1,844 ± 573 of SGAs in individual f, who did not progress to EA, but rather
opted for esophagectomy for high-grade dysplasia after 6.4 years of follow -up and
subsequently died of mesothelioma 11.9 years later. (Panels D, G) Consensus phylogenetic
trees estimated by BEAST reveal long-term co-existence of multiple clones. (Panels E, H, F,
I) Maximum parsimony trees reveal an underlying progressive evolution of SGA events
irrespective of time. Note in individual f that the clade defined by biopsies 1, 7, and 9 seem
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the most advanced in progression. Consensus phylogenetic trees generated as indicated in
the legend to Figure 4.

Figure 4.6. BEAST analysis of the SGA patterns across longitudinal biopsies within
individuals suggests that NSAID use reduces the SGA rate (number of SGA events per
genome, per year). For all individuals (a-m), the mean off-NSAID SGA rate was 7.8 (95%
support interval [SI]: 7.1–8.6) and the mean on-NSIAD SGA rate was 0.6 (95% SI: 0.3–1.5).
For participants a-k, the mean off-NSAID SGA rate was 8.8 (95% SI: 8.1–9.5,), whereas the
mean on-NSAID SGA rate was 0.2 (95% SI: 0.03–1.0). For the two participants l and m that
started surveillance on NSAIDs and then went off NSAIDs, there are mixed results. The
mean on-NSAID SGA rate for individual l was 3.1 (95% SI: 2.2–4.7) and the mean offNSAID SGA rate was 4.4 (95% SI: 3.1–5.9). However, for individual m the mean onNSAID SGA rate was 2.5 (95% SI: 2.1–3.0) and the mean off-NSAID SGA rate was 0.1
(95% SI: 0.01–0.6).

95

4.7. Supporting information

Supplementary Figure 4.7. Circos plots of individuals a,c,d,e,g,h,i,k, and m. Each ring
represents whole-genome SGA data from a different biopsy. Thin black line rings separate
endoscopies (time points), white background shows time periods off-NSAIDs and gray
background shows time periods on-NSAIDs. Within the rings, black segments designate
homozygous deletion, red single copy loss, orange copy-neutral LOH, and green shows copy
gain.
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Supplementary Figure 4.8. Estimated trees by BEAST for individuals a-m. Branch lengths
are scaled according to time, the tips of the phylogeny are biopsies aligned on the x-axis
according to their sampling time, and all internal nodes are estimated coalescence times
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assuming a logistic population growth model (see Methods). Dashed gray line represents the
time point of change in NSAID use. All these trees show long-term co-existence of clones
and no evidence of a clonal expansion taking over the Barrett’s segment.

Supplementary Figure 4.9. Estimated trees by PAUP trees where branch lengths represent
estimated number of SGA events for individuals a,c,d,e,g,h,i,k and m. The topology of these
trees suggest progressive accumulation of SGAs.
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Supplementary Figure 4.10. Estimated trees by PAUP trees where branch lengths represent
the total amount of SGA (Mb) of the estimated 0->1 SGA events from Supplementary
Figure 3 for individuals a,c,d,e,g,h,i,k and m.
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Supplementary Figure 4.11. Linear chromosome plot of SGAs that are common across all
biopsies within an individual. The most likely regions affected by SGA are fragile sites FHIT
and WWOX on chromosomes 3 and 16, respectively, as well as the p-arm of chromosome 9
that often includes the tumor suppressor gene CDKN2A. These are lesions that were
present by the time of the first endoscopy and so may have been established with the
hypothesized initial expansion of Barrett’s epithelium in competition with squamous
epithelium.
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Supplementary Figure 4.12. Linear chromosome plot of detected somatic genomic
abnormalities (SGAs) in biopsies from the baseline endoscopy (top panel), the first sampling
period (off-NSAIDs for a-k and on-NSAIDs for l, m; middle panel), and the second
sampling period (on-NSAIDs for a-k and off-NSAIDs for l, m; bottom panel).This plot
shows the genomic location and size of newly detected SGAs during off-NSAID (red) and
on-NSAID (green) periods that are summarized in Figure 3A. Black bars represent SGAs
observed in a prior sampling period or at baseline; top panel – black represents SGAs
detected in any biopsy from the baseline endoscopy; middle panel – black represents SGAs
detected in any biopsy from baseline endoscopy that is also detected in at least one biopsy in
the first sampling period; bottom panel – black represents SGAs detected in any biopsy from
baseline or first sampling period, or both, that is also detected in at least one biopsy in the
second sampling period. In the middle panel, red and green bars represent newly acquired
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SGAs that are detected in at least one biopsy in the first sampling period, but not detected at
baseline. In the bottom panel, red and green bars represent newly acquired SGAs that are
detected in at least one biopsy in the second sampling period, but not detected in any biopsy
from baseline or first sampling period.

To SGA absence (0)

To SGA presence (1)

From SGA absence (0)

1-α

α

From SGA presence (1)

0

1

Supplementary Equation S3. Substitution matrix (transition rate matrix) describing the
transition probabilities (rates) between SGA absence/presence (0/1) states that was
incorporated into BEAST. The probability α is the probability of acquiring SGA in a
segment in one division (at the biopsy level), which is estimated by the BEAST software.

P(1 | 0)  1  e t
P(0 | 0)  e  t
P(1 | 1)  1
P(0 | 1)  0
Supplementary Equation S4. Continuous-time solutions for the probability of all four
possible state transitions of a character on a branch of a phylogeny that has branch length of
t years.
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Individual

Sex

Age

L
(cm)

A
(cm 2)

X

K

Nt

Ib

Tr
(days)

Tinit
(years)

BEAST
Tinit
upper
bound
(years)

a

M 44

6

45

3

100,008

58,554

0.14

106

4.96

5.96

b

M 67

8

60

4

11,956

11,519

0.14

103

5.17

6.17

c

M 53

5

37.5

3

47,830

17,220

0.21

73

2.93

3.93

d

M 79

16

120

9

372,496

132,384

0.13

113

5.48

6.48

e

M 53

6

45

4

62,082

28,662

0.21

73

3.13

4.13

f

M 67

12

90

5

31,212

25,213

0.14

103

4.81

5.81

g

M 51

5

37.5

N/A N / A N / A N/A

N/A 4.74*

5.74*

h

M 62

5

37.5

3

33,750

15,000

0.16

93

3.77

4.77

i

M 55

5

37.5

5

44,080

16,840

0.09

161

6.49

7.49

j

M 47

7

52.5

5

90,104

69,671

0.11

133

6.63

7.63

k

M 45

4

30

2

34,147

13,978

0.14

103

4.11

5.11

l

M 53

14

105

3

55,985

33,523

0.14

103

4.62

5.62

m

M 50

5

37.5

3

22,115

11,020

0.1

145

5.75

6.75

56.5

4

72,480 36,132

0.14

109

4.81

5.81

Mean

55.8 7.5

Supplementary Table 4.1. Crypt density results. Age is the age of the individual at the first
endoscopy. L is the BE segment length measured as the distance in centimeters from the
GEJ to the OS anatomical landmarks; A is an estimate of the total area of the BE segment
by assuming a circumference of 7.5cm of the esophagus (estimated from [120]); X is the
number of levels that were biopsied and had slides from which various numbers of biopsies
were evaluated for counting the number of crypts and the number of branching crypts per
slide; K is an estimate of the maximum crypt count in BE segments extrapolated from the
maximum number of observed crypts in every scored level; N t is an estimate of the total
crypt count in BE segments at baseline endoscopy; Ib is the fraction of crypts that appear to
be branching in a sample of crypts; Tr is the estimated crypt doubling time in days (see
Equation S1); Tinit is the estimated time from initiation of the BE segment to baseline
103

endoscopy in years, assuming a logistic growth starting with 1 crypt that grows to a
population of N t crypts at baseline, and assuming a carrying capacity of K crypts for the BE
segment (see Equation S2); BEAST Tinit was bounded to 1 year earlier than the Tinit to allow
some flexibility in the estimate of the exact initiation date during the BEAST MCMC runs.
(*) We did not have crypt count information for individual g, so we estimated T init and
BEAST Tinit by taking the average from individuals c,h,i, and m since they had the same
segment length (5cm) as individual g.

State

Heterozygous SNPs profile

Homozygous SNPs profile

Log2R
AB
0
A
AA
AAA
AAB
AABB
AAAA

Allelic imbalance profile

Log2R

(-0.2,0.2)
(-3,-0.5)
(-3,-0.2)
(-1,0.15)
(1,2)
(0.15,1)
(1,3)
(1,3)

mBAF

(-0.15,0.2)
(-3,-0.5)
(-3,-0.15)
(-1,0.15)
(1,2)
(0.15,1)
(1,3)
(1,3)

(0,0.15)
(0,0.5)
(0.15,1)
(0.15,1)
(0.6,1)
(0.15,1)
(0,0.2)
(0.6,1)

Supplementary Table 4.2. Calling thresholds (lower and upper bounds given in parentheses)
used for identifying segments with single copy loss, double copy loss, copy gain, and copy
neutral LOH.
Individual

Colless Test
Yule null model

PDA null model

Sackin Test
Yule null model

PDA null model

P-values for tree shape imbalance of PAUP* phylogenetic trees
a
0.004
0.144
0
0.102
b
0.022
0.294
0.004
0.316
c
d

0.032
0

0.442
0.068

0.012
0

0.454
0.112

e
f
g

0.006
0.078
0

0.22
0.732
0

0
0
0

0.264
0.664
0

h
i
j

0
0.004
0.058

0.028
0.228
0.6

0
0
0.004

0.036
0.16
0.548

k
l

0.018
0

0.326
0.022

0
0

0.318
0.022

m

0

0.07

0

0.062

P-values for tree shape imbalance of BEAST phylogenetic trees
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a
b
c

0.03
0.124

0.442
0.552

0.006
0.018

0.376
0.498

d
e

0.772
0.95
0.492

0.968
0.996
0.918

0.13
0.258
0.08

0.93
0.998
0.868

f
g
h

0.664
0.448
0.016

0.992
0.882
0.26

0.154
0.096
0.002

0.978
0.904
0.3

i
j
k

0.034
0.176

0.49
0.714

0
0.042

0.444
0.79

0.98
0.01
0.158

1
0.27
0.696

0.294
0.002
0.044

1
0.316
0.658

l
m

Supplementary Table 4.3. Tree shape imbalance statistics for individuals a–k estimated for
PAUP* and BEAST trees calculated from generating 500 random trees having the same
number of taxa under Yule and PDA null models [121] using the R package “apTreeshape”
[122]. Significant p-values reject the null hypothesis that the observed tree shape is as
balanced as the 500 random tree shapes, where the test statistics are the Colless and Sackin
formulas [121] for calculating tree shape imbalance.
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Supplementary Figure 4.13. Raw data segmentation and SGA calls for all 161 biopsies of
individuals a–m. Every page shows an individual biopsy and has 5 panels (top to bottom):
first panel, raw Log 2R ratio between biopsy and leukocyte control, where gray SNPs are
homozygous SNPs and black SNPs are heterozygous SNPs; second panel, GLAD
segmentation of homozygous SNPs (blue line) and heterozygous SNPs (red line); third
panel, raw mBAF (reflected and scaled B Allele Frequency of the BE sample) where
homozygous SNPs are shown in gray, and heterozygous SNPs are shown in black; fourth
panel, GLAD segmentation of the mBAF data of heterozygous SNPs, which are informative
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for allelic imbalance; fifth panel, final SGA calls for chromosomal regions: GN (copy gain,
green), CNLOH (copy neutral LOH, orange), SD (single deletion, or single copy number
loss, red), HD (homozygous deletion, or double copy number loss, black). Only one example
biopsy is displayed here, which is biopsy #8 from individual j, which shows massive SGA.
4.7.1. Cell organization into crypts in Barrett’s Esophagus and Analytical modeling of
crypt production in Barrett’s esophagus (Supplementary Text S1)
To understand how evolution at the genome level unfolds, we need to first consider how
cells are spatially organized in the BE tissue. The BE epithelium is a single layer of
specialized intestinal metaplasia that typically covers 38 cm 2 and contains between 10,000400,000 crypts (Supplementary Table 4.1). Crypts hold a reservoir of stem cells at their base
that are self-renewing cells capable of generating and propagating genomic alterations over
long timespans. Cell proliferation and differentiation occurs at the base of the crypts
producing a flux of differentiated cells that move up the crypt and slough off into the lumen.
Because of this constant shedding of cells, cell fitness in a crypt-structured epithelium is a
complex combination of stem cell self-renewal, survival, and lateral spread, taking over
neighboring crypts. Acquired SGAs that boost any of these three cell phenotypes will persist
and increase in frequency in the BE cell population. The organization of cells into crypts in
itself is an evolved mechanism to protect against cancer since acquired SGAs in
differentiated cells can be lost by cells sloughing off and only acquired SGAs in stem cells
can persist and increase in frequency over time; and also, in a strictly single-layer columnar
epithelium, lateral invasion of mutant cells into neighboring crypts is physically difficult since
invading from the lumen side requires going against the flux of cells [17]. A subset of SGAs
were detected in all biopsies of an individual over decades (Supplementary Figure 4.11)
which is evidence that these SGAs must be acquired in long-living self-renewing (stem) cells

107

that have not differentiated, been sloughed into the lumen, and have survived toxic
microenvironmental exposures. Other SGAs had various lifespans in the segment (Figures
Figure 4.2, Figure 4.4B,C, Figure 4.5B,C, Supplementary Figure 4.12) but only a fraction of
them were turning over, either appearing or regressing (Figure 4.3). In summary, the spatial
organization of cells into a single-layer crypt-structured BE epithelium constrains the
evolutionary dynamics and spatial dispersal of acquired SGAs over time.

Tr 

Tb log 2
log(1  I b )

Supplementary Equation S1. Estimating the crypt doubling time where the duration of
branching (Tb) is set to 20 days; see Appendix I from [97]. Ib is the fraction of crypts that
appear to be branching in standard pathology slides of BE biopsies.
The duration of the crypt replication cycle Tr can also be defined as a crypt doubling time, in
both definitions Tr is the time it takes, in days, for a single crypt to replicate and produce tw o
daughter crypts. This equation assumes exponential growth, where the number of crypts at
time t is [123]:

N (t )  N (0)e

log 2
t
tr

Often, population growth is expressed using a growth rate parameter, or Malthusian growth
parameter, m, which is:

m

log 2
tr

Although simple mathematically, exponential growth is not realistic for biological systems,
where when populations grow in size and density, the competition for space and resources
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increases, which causes growth to slow down. Such behavior can be modeled with a logistic
growth equation, which is one type of sigmoid functions, which introduces the concept of
carrying capacity, or maximal population size. As the population size reaches its carrying
capacity, its growth rate decreases.
In Barrett esophagus, the date of the most recent common ancestor (MRCA) of all biopsies
(or time from initiation to baseline endoscopy) can be identified if logistic growth is
assumed. For the logistic growth, the Barrett segment is initiated with a single crypt, i.e. at
time Tinit, the crypt population size is N 0=1. At time t of baseline endoscopy, the crypt
population size is N t, and for the duration of evolution, the maximal crypt population size is
K. The following logistic equation describes the duration of the initiation phase Tinit which is
in units of days, since Tr is also in units of days:

Tinit 

N (K  N 0 )
Tr
log t
log 2
(K  Nt )N 0

Supplementary Equation S2. Estimating the initiation phase duration, where N0=1 is the
starting population size that is fixed to 1 crypt. K is the estimated maximum number of
crypts (“carrying capacity”) in a BE segment , Nt is the estimated total number of crypts in a
BE segment, and Tr is the crypt doubling time defined in Supplementary Equation S1.
Where Ib is the fraction of branching crypts, calculated by taking the average number of
branching crypts for each level and dividing by the average number of crypts for that level
(for each level, 1-4 pathology slides were counted), choosing the level with maximum
number of branching crypts. L is the segment length (cm), or the distance between the low er
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esophageal sphincter (LES) and ora serrate (OS) landmarks. A is the surface area, calculated
by multiplying L and the circumference of the esophagus, which is fixed at 7.5 cm
(approximately the diameter of a US quarter coin). K is the carrying capacity, calculated by
taking the maximum number of crypts detected in any one of the slides within a level, and
summing those counts across levels to get the maximum possible crypt count per segment.
Nt is the average crypt count per level, calculated by taking the crypt count for each slide and
dividing by the number of slides, and extrapolating to the level surface area. X is the number
of levels that were scored by pathology out of L possible levels.
Comparison of % branching crypts in normal and diseased epithelium
Ib is the observed fraction of crypts that appear to be budding or branching in a sample of
crypts, isolated from a crypt-structured epithelium (Barrett’s epithelium, small intestinal or
colonic epithelium). Often, Ib is measured by incubating the tissue in EDTA and peeling off
the epithelium from stroma, after which, crypts could be scored as budding or branching by
visual examination under a dissecting microscope. Alternatively, Ib can be estimated from
H&E stained histopathology slides, however, only crypts that show the majority of the crypt
lumen, ideally both the crypt bottom and the crypt mouth, can be safely counted as budding
or branching. For simplicity, the term “branching” would mean crypts that are either
budding or branching, since both appearances are part of the branching process, therefore Ib
counts both budding and branching crypts.
My estimates of Ib from Srivastava and Odze’s pathology slide measurements ranged 9%21% (mean 14%) and fall within the ranges of two previously reported crypt branching rate
estimates in the literature. Cheng et al. reported an average of 0.44%, 30.4%, 15.1%, and
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13.2% branching crypts in 11 normal adults, and 4 Ulcerative colitis, 4 Crohn’s disease, 4
Multiple polyposis patients [97]. The average ages and age ranges of the four groups were 69
(48-83), 47(31-56), 33 (27-45), and 42 (34-56) [97]. Cummins et al. reported an average of
7.8%, 15%, 4.9%, 1.7% branching crypts in small intestine in 3 neonates, 16 infants, 14
children, and 39 adults [124]. The average ages and age ranges of the four groups were 2.4
weeks (0.9-4 weeks), 0.7 years (0.3-1.7 years), 7.9 years (2.4-16.2 years), and 46 years (20-80
years) [124]. Therefore, it is likely that in hyperproliferative Barrett tissues crypts attain a rate
of branching similar during pregnancy and infancy, surpasses the branching rate in adult
normal intestinal epithelium, and compares to rate of branching in diseased colonic
epithelium.
4.7.2. Detecting mutation rate change in Barrett’s esophagus after treatment with
NSAIDs: computational power analysis
Authors: Rumen Kostadinov, Mary Kuhner, Carlo Maley
4.7.2.1. Introduction and Methods
I performed in-silico analysis in 2007 prior to conducting the large study in this Chapter to
calculate the power to detect mutation rate changes, which was critical for selecting the
number of time points and the number of biopsies per time point to assay per individual
patient, given the high cost of whole-genome SNP assays. I modified SerialSimCoal [63] to
simulate an evolving tumor cell population with the following parameters:
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24 samples over 10 years
4 samples every 2 years (=6 time points)
300 cell generations per year
8,000 neutral loci (no natural selection)
1.1, 2, 5, 10 and 100-fold decrease in mutation rate after year 5
AR – ancient mutation rate (off NSAIDs) (5 year duration)
RR – recent mutation rate (on NSAIDs) (5 year duration)
Effective population size, N e = 100, 1000, 10000
Constant population size over time
Population-scaled mutation rate (theta) θ = 0.000082, 0.00082,
0.0082
Table 4.4. Parameter table for the in-silico power analysis.
I used BEAST [62,107] to estimate population sizes and mutation rates before and after year
5, given 24 samples. I adapted SimCoal and BEAST to use sequences of 0s and 1s
representing absence and presence of LOH, and used a novel two-state LOH substitution
model. I adapted the BEAST software for coalescent-based backward estimation of
population genetic parameters given SGA data. I made three major changes to BEAST:
addition of a 0/1 binary evolutionary model, addition of a sequence error, and addition of an
extra MRCA-LUCA branch.
First, I included a 0/1 binary evolutionary model that instead of having four DNA states
A,C,G, and T, which are modeled with DNA evolutionary models such as Jukes-Cantor or
F84, has only 2 possible states, 0 and 1, and allows 0->1 and 1->0 transitions. If the
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probability of 0->1 transition is alpha and the probability of 1->0 transition is beta for one
step of the Markov chain then a continuous approximation can be derived for the state of
the chain after t steps, where t can be a decimal (Dr. Joseph Felsenstein, personal
communication). I implemented this 0/1 model into BEAST allowing the user to specify
alpha and beta as parameters. Notably, if we would like to make an irreversible model by
disallowing 1->0 transition, we simply set the 1->0 probability beta to 0. The 0/1 model, as
any other evolutionary model, simply calculates the likelihood of starting at a given state at a
parent node in a phylogeny and ending at any other state at a child node in a phylogeny
given a certain branch length or distance between the parent and child nodes.
Second, I implemented a sequence error in BEAST. An observed state in a sequence could
be incorrect prone for example due to instrument technical errors. Typically in DNA
evolutionary models a sequence error is modeled by replacing the likelihoods of A, C, G, T
at a site (terminal node, or tip) that is called "A" by the assay from 1, 0, 0, 0 to 1-e, e, e, e,
where e is the sequence error [125].
I adapted SerialSimCoal software [63] for coalescent-based forward simulation of SGA data
given population genetic parameters. SerialSimCoal is a forward simulation of population
dynamics and various evolutionary models can be used to simulate serial samples given a
specified demographic history. I made changes in SerialSimCoal to produce 0/1 data where a
change from 0->1 is irreversible, and where the ancestral state of the population is always 0.
The modified versions of BEAST and SerialSimCoal are available upon request.
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4.7.2.2. Results and Discussion
For 91% (41/45) of the parameter combinations, we had >80% power to detect a 1.1- to
100- fold decrease in mutation rate (paired Wilcoxon test, p<0.05) (Table 4.5). As the fold
difference in mutation rate increased between ancient and recent periods, the number of
parameter sweeps that accurately estimated the simulated mutation rates increased (third and
last column of Table 4.5). Overall, BEAST recovered mutation rates accurately from
simulated data, which verified that the implementation of the novel 0/1 evolutionary model
was accurate and error-free.
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True
Ne
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
10000
10000
10000
10000
10000
10000
10000
10000
10000
10000
10000
10000
10000
10000
10000

Theta

Fold
Diff.

Ne 95%
CI lower

Ne 95%
CI
upper

8.25E-05
8.25E-05
8.25E-05
8.25E-05
8.25E-05
8.25E-04
8.25E-04
8.25E-04
8.25E-04
8.25E-04
8.25E-03
8.25E-03
8.25E-03
8.25E-03
8.25E-03
8.25E-05
8.25E-05
8.25E-05
8.25E-05
8.25E-05
8.25E-04
8.25E-04
8.25E-04
8.25E-04
8.25E-04
8.25E-03
8.25E-03
8.25E-03
8.25E-03
8.25E-03
8.25E-05
8.25E-05
8.25E-05
8.25E-05
8.25E-05
8.25E-04
8.25E-04
8.25E-04
8.25E-04
8.25E-04
8.25E-03
8.25E-03
8.25E-03
8.25E-03
8.25E-03

1.1x
2x
5x
10x
100x
1.1x
2x
5x
10x
100x
1.1x
2x
5x
10x
100x
1.1x
2x
5x
10x
100x
1.1x
2x
5x
10x
100x
1.1x
2x
5x
10x
100x
1.1x
2x
5x
10x
100x
1.1x
2x
5x
10x
100x
1.1x
2x
5x
10x
100x

45
48
49
44
52
64
62
63
62
205
322
307
584
1064
2814
407
401
467
448
564
615
653
614
635
695
699
726
690
703
695
1588
1868
2646
3261
4738
5175
4659
5350
5731
6425
6557
6750
6769
6771
7057

277
297
271
237
208
183
178
204
178
1033
1544
1615
4449
7055
25807
18016
12370
7413
3675
2095
2082
2079
1867
1834
1832
1729
1778
1685
1714
2108
67909
74827
74952
73887
65189
63593
54874
51011
41713
26243
28239
24801
21222
19895
17568

True AR

AR 95%
CI
lower

AR 95%
CI
upper

True
RR

RR 95%
CI lower

RR 95%
CI
upper

No.
sweeps
cover.
Ne

No.
sweeps
cover.
AR

No.
sweeps
cover.
RR

4.3E-07
5.8E-07
9.2E-07
1.3E-06
4.1E-06
4.3E-06
5.8E-06
9.2E-06
1.3E-05
4.1E-05
4.3E-05
5.8E-05
9.2E-05
1.3E-04
4.1E-04
4.3E-08
5.8E-08
9.2E-08
1.3E-07
4.1E-07
4.3E-07
5.8E-07
9.2E-07
1.3E-06
4.1E-06
4.3E-06
5.8E-06
9.2E-06
1.3E-05
4.1E-05
4.3E-09
5.8E-09
9.2E-09
1.3E-08
4.1E-08
4.3E-08
5.8E-08
9.2E-08
1.3E-07
4.1E-07
4.3E-07
5.8E-07
9.2E-07
1.3E-06
4.1E-06

2.2E-07
2.9E-07
5.1E-07
8.4E-07
3.1E-06
3.3E-06
4.7E-06
7.6E-06
1.1E-05
3.4E-05
3.3E-05
4.4E-05
5.6E-05
7.6E-05
5.4E-05
8.9E-09
1.8E-08
3.5E-08
6.0E-08
2.4E-07
2.5E-07
3.6E-07
6.3E-07
9.2E-07
3.4E-06
3.6E-06
4.9E-06
8.0E-06
1.2E-05
3.7E-05
8.7E-10
1.1E-09
1.8E-09
2.5E-09
1.0E-08
1.1E-08
1.6E-08
2.7E-08
5.2E-08
2.2E-07
2.1E-07
3.3E-07
5.7E-07
8.7E-07
3.4E-06

9.1E-07
1.0E-06
1.5E-06
2.1E-06
5.3E-06
5.6E-06
7.4E-06
1.1E-05
1.5E-05
4.2E-05
4.3E-05
5.5E-05
8.1E-05
1.1E-04
2.1E-04
1.6E-07
2.0E-07
2.5E-07
3.3E-07
7.0E-07
7.0E-07
8.8E-07
1.3E-06
1.8E-06
5.0E-06
5.3E-06
6.8E-06
1.0E-05
1.5E-05
4.4E-05
6.9E-08
6.6E-08
6.1E-08
6.7E-08
1.1E-07
1.1E-07
1.3E-07
1.8E-07
2.5E-07
6.0E-07
6.4E-07
8.4E-07
1.2E-06
1.6E-06
4.8E-06

3.9E-07
2.9E-07
1.8E-07
1.3E-07
4.1E-08
3.9E-06
2.9E-06
1.8E-06
1.3E-06
4.1E-07
3.9E-05
2.9E-05
1.8E-05
1.3E-05
4.1E-06
3.9E-08
2.9E-08
1.8E-08
1.3E-08
4.1E-09
3.9E-07
2.9E-07
1.8E-07
1.3E-07
4.1E-08
3.9E-06
2.9E-06
1.8E-06
1.3E-06
4.1E-07
3.9E-09
2.9E-09
1.8E-09
1.3E-09
4.1E-10
3.9E-08
2.9E-08
1.8E-08
1.3E-08
4.1E-09
3.9E-07
2.9E-07
1.8E-07
1.3E-07
4.1E-08

1.9E-07
1.3E-07
7.1E-08
4.3E-08
1.3E-08
2.9E-06
2.1E-06
1.2E-06
8.1E-07
1.8E-07
3.6E-05
2.7E-05
1.7E-05
1.2E-05
2.9E-06
9.7E-09
8.0E-09
6.0E-09
3.3E-09
2.6E-09
2.1E-07
1.5E-07
8.9E-08
5.4E-08
1.5E-08
3.2E-06
2.3E-06
1.4E-06
9.1E-07
2.3E-07
1.8E-09
1.4E-09
1.1E-09
9.5E-10
1.6E-09
1.2E-08
7.0E-09
5.4E-09
4.5E-09
3.1E-09
2.2E-07
1.3E-07
7.5E-08
4.5E-08
1.3E-08

8.7E-07
7.2E-07
5.6E-07
4.6E-07
3.2E-07
5.0E-06
3.9E-06
2.7E-06
2.1E-06
8.5E-07
4.4E-05
3.3E-05
2.3E-05
1.6E-05
5.4E-06
1.7E-07
1.7E-07
1.6E-07
1.4E-07
1.3E-07
6.8E-07
5.6E-07
4.3E-07
3.5E-07
2.1E-07
4.8E-06
3.7E-06
2.5E-06
1.9E-06
7.5E-07
9.0E-08
8.4E-08
7.1E-08
7.1E-08
8.8E-08
1.4E-07
1.3E-07
1.3E-07
1.4E-07
1.6E-07
6.7E-07
5.5E-07
4.6E-07
4.2E-07
3.3E-07

93
93
93
96
95
94
91
91
93
89
81
83
79
78
46
96
95
96
97
98
97
92
94
97
88
91
93
97
96
95
96
97
98
98
93
94
97
92
92
89
96
96
95
94
94

97
93
93
94
89
98
96
97
94
90
87
86
77
75
26
98
96
92
94
95
93
92
95
93
96
94
98
95
93
95
99
99
98
96
92
93
98
94
90
92
94
92
95
95
94

93
96
95
97
92
93
97
97
96
94
86
86
82
91
94
96
95
93
96
77
93
96
93
98
95
98
95
98
97
96
95
87
85
85
10
95
95
92
91
78
92
97
93
93
94

No.
sweeps
AR>RR
p<.05
n=100
91
90
99
100
100
83
100
100
100
100
97
100
98
100
99
82
82
95
98
100
88
98
100
100
100
91
100
100
100
100
80
75
75
73
81
82
83
92
90
99
85
96
100
100
100

Table 4.5 BEAST inference of mutation rates on and off NSAIDs and of constant
population size from samples generated from a SerialSimCoal forward simulation using a
fixed set of mutation rates on and off NSAIDs and a fixed constant population size.
4.7.2.3. Conclusion
This power analysis helped in getting grant funding and in study design of the larger
experiment that tested the hypothesis that an association between mutation rate change and
NSAIDs use exists. This power analysis was presented at the AACR Frontiers in Cancer
Prevention conference in Philadelphia in 2007.
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4.8. Chapter conclusion
In summary, our results suggest that in most individuals in long-term endoscopic
surveillance with BE, clonal evolution within the BE segment has occurred prior to baseline
detection in the clinic, but from baseline detection to more than a decade of follow -up the
population remains in relative evolutionary stasis at the genome level. Only rarely is
evolutionary stasis punctuated by a massive burst of SGA that may lead to progression to
cancer. The current picture supports an evolutionary scenario in which mutation-selection
balance of spontaneous SGAs and purifying selection against deleterious effects maintain a
relative stasis of the genome until a chance occurrence of adaptive (for the clone) SGA,
perhaps with epistatic effects, or changes in the selective environment, results in a new
proliferating clone that may progress to EA. In addition to the observation of evolutionary
stasis, NSAID use in Barrett’s esophagus is associated with a reduction in the rate of
acquisition of SGA suggesting that the pathway whereby NSAIDs exert their protective
effect involves the reduction in number of SGAs or the inhibition of spread of SGAcontaining clones. Finally, detection of evolutionary stasis might be used in the clinic to
reduce overdiagnosis and unwarranted treatment and detection of massive bursts of SGA
might be used to better identify patients needing more aggressive surveillance and therapy.
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Chapter 5. Pilot in vitro experiment evaluating the genotoxic
effect of deoxycholic acid on the evolutionary dynamics of SGA
Author: Rumen Kostadinov
5.1. Introduction
Studying the evolutionary dynamics of SGA in vivo in humans has many limitations due to
the infeasibility for performing a fully controlled experiment. Ideally, we aim to study the
evolution of cell lineages carrying acquired SGA under the presence or absence of genotoxic
constituents of duodenal gastroesophageal reflux. However, in vivo, administering genotoxic
compounds in a controlled experiment is unethical and unfeasible. Therefore, we designed
an experimental evolution study to evaluate the in vitro SGA evolutionary dynamics in a
Barrett’s esophagus cell line, where we controlled the dose and duration of genotoxic stress
and observed the acquisition of SGA in evolving cell lineages over time. Ultimately,
modulating the dose and duration of genotoxic stress corresponds to modulating the
mutation rate, or the rate of acquisition of SGA, which is a key population-genetic parameter
providing a quantity of the raw material that allows for evolution by natural selection to
occur. Moreover, we aimed to develop computational and statistical methods for estimating
SGA rate in order to test whether the inferred SGA rate from observed patterns of SGA in
vitro correlates positively to the level of genotoxic exposure to which we subject the cell line.
In summary, the experimental evolution study allowed us to evaluate the relationship
between the level of DCA genotoxicity, the level of detected SGAs, and the evolution of
SGAs that we define as the change in the frequency of SGA over an approximately similar
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number of cell generations under presence of various levels of DCA or absence of DCA
exposure.
Jenkins et al. showed that the bile acid deoxycholic acid (DCA) is genotoxic and may be
associated with the acquisition of SGA and carcinogenesis in BE [10,126]. Therefore, we
selected DCA as the source of mutational input to the cell lines. Jenkins et al. tested various
concentrations of DCA, ranging from 0-400μM in an approximately fixed concentration of
esophageal cells (105 cells/mL) (See Fig. 1 in Ref.[126]). I also tested the effect of various
concentrations of DCA on relative cell viability, since we aimed to achieve low and high
mutation rates that both retain cell viability so that we can assay the cells’ genomic state over
time.
5.2. Methods

Figure 5.1. Study design of single cell experimental evolution. Single cells from an ancestral
cell population from a CP-D Barrett’s cell line were grown in 96 well plates, where cells were
plated at a concentration of 1/3 of cells per well. Cells were passaged into larger 6-well plates
and T25 and T75 plates as they grew in number. After two rounds of single cell cloning,
DNA was extracted from 8 samples (samples #1-#8) and DNA was evaluated with Illumina
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550K arrays at the Penn Hospital of the University of Pennsylvania (HUP) genomics facility.
The two rounds of single cell cloning ensure that any difference in genomic state between
samples #5 and #6, #7 and #8, #2 and #1, and #3 and #4 occurred during the course of
the experiment (under the various deoxycholic acid (DCA) concentrations).
BE cell line ID

CP-D

BE cell line name

CP-18821

Method of Initiation of Primary Cultures

Enzymatic

Biopsy extracted from region of:

High-grade dysplasia

Serum-Free adapted, Keratinocyte serum-free media
(Invitrogen catalog no. 17005-042)

Yes

Doubling Time (hrs)

32.26

DNA content

2.43 (4.56 subpopn)

% 4N DNA

28.5

Tetraploid (%)

15.8

17p LOH

Yes (in vitro) No (in vivo)

P53 mutation

Frameshift 302

P53 mutation

Not detected in vivo

9p LOH

Homozygous deletion (4N,
8N)

CDKN2/p16

Deletion of C5.1 STS marker
(4N, 8N)

5q LOH

No

Fluorescently tagged populations

GFP, DsRed

Table 5.1. CP-D Barrett’s esophagus cell line description
I used a Barrett’s esophagus cell line named “CP-D” or “CP-18821”, which was described in
Palanca-Wessels et al. (Table 5.1) (M. C. Palanca-Wessels et al. 1998; M. C. A. PalancaWessels et al. 2003).
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CP-D cells were cultured in KSFM media (Invitrogen) supplemented with 25mg of bovine
pituitary extract, 2.5ug recombinant epidermal growth factor (Invitrogen), 50 units of
Penicillin, and 50ug Streptomycin, per 500mL of media. Cells were initially diluted and
distributed into wells of a 96 well plate at a dilution of 1/3 of a cell per well. Assuming a
Poisson distribution, (formula in R: “dpois(# of expected cells per well,1/3)*96”), this
results that on average ~23 wells would be expected to contain a single cell, and on average
~4 wells would be expected to contain two cells, and on average ~69 wells would be
expected to contain no cells. After ~1-24 hours, once the cells attached to the surface of the
plate, the wells were examined under a phase and under a fluorescent microscope to record
wells that were initiated with a single cell. Conditioned, filtered media from CP-D cell
cultures was used to facilitate clonal expansion when the clones are at low density. After cell
growth reached near confluency within the wells of a 96-well plate, cells from the wells are
trypsinized and transferred to a 6-well plate. Clones were passaged to larger plates as they
grow so that they are never allowed to become confluent.
Cells are initially diluted and distributed into wells of a 96 well plate such that on average less
than 35 wells contain cells and on average 10 out of the 35 wells contain a single cell. After
24 hours, once the cells have attached, the wells are examined under a light microscope using
the objective lens set at 4X and 10X magnification to count the number of cells in each well
of the 96 well plate. Conditioned, filtered media from CP-D cell cultures is used to facilitate
clonal expansion when the clones are at low density. While the cells grow in a 96 well plate,
they receive media change once per week. After 23 days, cells from the wells that were
initiated with a single cell are trypsinized and transferred to a 6-well plate. At the 6-well plate
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stage, fresh KSFM media is used only and media is changed every 3-5 days. Clones are
passaged to larger plates as they grow so that they are never allowed to become confluent.
I designed and followed the following protocol for preparing a DCA+KSFM solution:
1. A solution was made that contains both KSFM media and 250μM DCA. The final
volume of this solution is 40mL. The molar mass of DCA is 392.6 g/mol, therefore
to make 250μM DCA solution in 40mL, 3.926mg of DCA was measured (grams
DCA= 0.04 L * 0.00025 mol/L * 392.6 g/mol). To measure such a tiny amount, I
tared the scale instrument with an empty eppendorf tube, and then dispensed
miniscule amounts of DCA powder into the tube to bring it to approximately 3.9mg.
The final weight typically ranged between 3 and 5 mg due to the precision of
dispensing such tiny amount of powder by hand into an eppendorf tube. At the 35mg extremes, the final solution would range between 191μM and 318μM, which
was not far off the desired 250μM concentration.
2.The DCA powder was poured from the eppendorf tube into a beaker containing 40mL
of KSFM. A magnetic stir bar and a hot plate (with the heat off) were used to
dissolve the DCA into the solution, which typically took 40-50 mins of stirring. After
dissolving, a filtered syringe was used to transfer the contents of the beaker to a
50mL plastic centrifuge tube. From that final 40mL 250μM DCA+KSFM solution, I
prepared 0.1μM, 1μM, and 10μM solutions by dilution with fresh KSFM media,
whenever cells needed fresh media, or whenever cells needed to be passaged from
96-well plates into 6-well plates and into larger plates.
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5.2.1. Results and Discussion
When I tested concentrations of 50μM, 100μM, 250μM, and 500μM DCA on the single cell
96-well plates, all cells died within a few days, or, no cell growth occurred in that any single
well can reach confluency.

Figure 5.2. An example composite image from phase contrast and GFP fluorescence images
under a 10x magnification of CP-D cells in a 6-well plate after several weeks of growth from
a single starting cell.
CP-D cells have elongated sickle-like or ball-like shape and express high levels of green
fluorescent protein (GFP). These images are taken several weeks after single cell cloning, i.e.
all of the cells descent from a recent common ancestor cell that was seeded several weeks
prior to the time of imaging.
DCA had a dose-related effect on inducing SGA in CP-D cells. The log 2-transformed signal
intensity R ratio between cloning round 2 versus cloning round 1 revealed differences
between the rounds indicative of acquired SGAs. For example, taking the log2 ratio between
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round 1 and round 2 of the same clone under 1μM DCA revealed a SGA that was ~20Mb in
size on chromosome 22 (Figure 5.3).
DCA appeared to induce microdeletions throughout the genome however rarely it seemed
to be able to induce a large-scale SGA (Figure 5.3) similar to large scale SGAs seen in
individuals a-m (Supplementary Figure 4.12) and in chromosome 9p of the single individual
(Figure 2.6).

Figure 5.3. Comparing two rounds of single cell cloning revealed an acquired SGA that was
approximately 20Mb in size on chromosome 22 in the clone that was grown under 1μM
DCA (Panel C). In comparison, the clones grown under 0μM (control, panel A), 0.1μM
(panel B), and 10μM DCA (panel D) show no apparent SGA at the same location. This
result suggests that the bile acid DCA is capable of inducing large-scale SGA, as much as
20Mb in size, in a BE cell line in vitro. Importantly, the physiological doses of DCA in
humans in vivo can be as much as 50-100μM [126].
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Figure 5.4. B allele frequency plots of all 8 samples from round 1 and round 2 of single cell
cloning under 0μM (control, panels A,B), 0.1μM, 1μM and 10μM DCA exposure. Note that
the 1μM DCA clone in round 2 acquired the ~20Mb single copy loss (Panel F) since no
heterozygous SNPs are observed and the total signal intensity R is lower than the same clone
froum round 1. (Figure 5.3, Panel C).
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Figure 5.5. Histograms of the number and size of copy number alterations detected in
evolving CP-D clones in vitro due to 0μM (control), 0.1μM, 1μM and 10μM DCA exposure
to DCA, a genotoxic component of duodenal gastroesophageal reflux in individuals with
Barrett’s esophagus. Higher concentrations of DCA induce more and/or larger lesions.
I tested CP-D cells to determine if we could generate genetic lesions in culture. I used two
rounds of single cell cloning to ensure that any differences between samples after the first
and second round of cloning would be due to lesions that occurred during the course of the
experiment, rather than due to sampling of different genotypes from a heterogeneous
parental cell culture. I analyzed the results of Illumina 550K SNP arrays with the GLAD
algorithm to identify regions of copy number differences between the first and second
rounds of cloning. I tested exposures to a range of concentrations (0, 0.1, 1 and 10uM) of
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deoxycholic acid (DCA), a genotoxic component of gastroduodenal reflux in patients with
BE. Figure 5.5 shows that the number and size of lesions we detected. Without a normal
sample for comparison, LOH cannot be distinguished from constitutive homozygosity, so
we have focused on copy number changes here.

Sample ID

Condition

96-well ID

Round

1

1uM DCA

B9

2

2

1uM DCA

F10

1

3

10uM DCA

C2

1

4

10uM DCA

B5

2

5

control

D12

1

6

control

F3

2

7

0.1 uM DCA

B7

1

8

0.1 uM DCA

D7

2

Table 5.2. Illumina 550k-SNP arrays were used to evaluate 8 samples for somatic
abnormalities.
5.2.2. Conclusion
I showed that increasing dose of DCA incurred somatic genomic abnormalities in DNA of
CP-D cells. This work contributed to successfully getting the American Cancer Society grant
for measuring somatic mutation rate associated with NSAID exposure. NSAIDs exposure
and DCA exposure may manifest in the same way in modulating the acquisition of somatic
genomic abnormalities over time. Studying the modulating effect of NSAID exposure in vitro
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is difficult because it warrants constructing an immune response and inflammation in cell
culture. Future studies in experimental cell culture evolution may further the development of
computational methods of estimating the types and rates of somatic genomic abnormalities
acquisition.
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Chapter 6. Conclusions
6.1. Thesis
Epithelial esophageal adenocarcinoma is a disease of the somatic genome, the etiology of
which is dependent on evolution by natural selection of somatic cells. I hypothesize that
neoplastic cell populations in Barrett’s esophagus maintain evolutionary stasis over decades
despite having a genome, 1-3% of which is riddled with acquired somatic genomic
abnormalities; and occasionally when massive amount (20% or more) of genomic
abnormalities are detected in association with a local clonal expansion, the neoplastic cell
populations can evolve and manifest malignancy. I also hypothesize that the puzzling
phenomenon that 90-95% of individuals with Barrett’s esophagus retain a benign course
over time and never progress to esophageal adenocarcinoma is explained by the observations
that evolutionary genomic stasis is maintained over decades in Barrett’s neoplastic cell
populations, which I have shown in one individual in Chapter 2 and in 12 individuals in
Chapter 4. It has not escaped my attention that the same may hold true for other epithelial
pre-malignant neoplastic conditions and their associated malignancies.
6.2. Future directions for research in evolution in cancer
My doctoral research is an example of applying methods in evolutionary biology to cancer
data. While the title of this dissertation reads “evolutionary dynamics” I conclude with
exposition of relative evolutionary stasis in Barrett’s neoplastic cell populations. How does
neoplastic evolution play out in Barrett’s esophagus individuals over decades? While the
predominant conceptual framework for neoplastic evolution is stepwise accumulation of
genetic abnormalities [127], or gradualism model, our longitudinal observations in Barrett’s
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individuals suggest stochastic bursts of acquisition of abnormalities and maintenance of the
status quo in the majority of the genome, more consistent with a “punctuated equilibrium”
model put forward for species-level evolution [128] . While our in silico modeling of genetic
diversity predicts a monotonic increase over two decades, at the resolution of profiling the
genomic state of biopsies and at the resolution of our sampling, our in vivo observations
support maintenance of SGA amount which also translates to maintenance of genetic
diversity with little relative change over time.

Massive somatic genomic abnormalities can be acquired in neoplastic cell populations,
however, the in vivo evidence presented in Chapter 4 cannot distinguish conclusively whether
a single cell mitosis or multiple cell mitoses induce massive amount of genomic
abnormalities. There is an ongoing trial and error process during carcinogenesis, generating
some cell lineages that persistently survive in neoplasms, and other cell lineages that only
transiently survive and eventually die out outcompeted in the evolutionary race for survival.
While conceptually, stages of carcinogenesis can be divided into initiation, promotion, and
progression, the evolutionary process in neoplasm need not necessarily proceed in discreet
steps, but rather manifest a continuum that is punctured by stochastic acquisition of SGAs.
The in vivo evidence presented in Chapter 4, in my view, suggests a rugged fitness landscape
where a massive SGA can elevate a cell to a stable fitness plateau sufficient to induce
increase in numbers so that the cell transforms into a clonal population of cells. Any steps
away from such plateaus or adaptive peaks tend to generate cells lineages having
evolutionary dead ends, or not enough time is available for successful crossovers to other
adaptive peaks in the genotype landscape. This is one plausible explanation of the apparent
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evolutionary stasis. Even in the massive SGA clone in individual j (Chapter 4, Figure 4.4)
that clone had a mean SGA genotype of 588±18 Mb altered of the genome for a time
interval of 3 years and being detected in 4 biopsies. That could be interpreted that the 588
Mb of SGAs that are approximately in common across the 4 biopsies form the genotypic
configuration representing the adaptive peak of that clone within the fitness landscape. And
the 18 Mb of standard deviation of SGA amount represents a tolerable deviation of ongoing
trial and error in genotype space around that stable adaptive peak. Similarly, for most
individuals, except b,j, and f, the detection of 53±30 Mb SGA amount could be interpreted
as a stable adaptive peak of 53 Mb SGA, comprising mostly losses on chromosome 9 and
fragile sites, and a 30 Mb of SGA trial and error around that adaptive peak, representing
stochastic acquisition, retention, and purging of persistently or transiently surviving SGAs.
Is there an optimality criterion for a changed genome for manifesting persistent survival and
clonal expansion? Certainly, baseline SGAs that are common across all 13 individuals (SGAs
shown in black, Chapter 4, Supplementary Figure 4.12) are associated with the initial clonal
expansion, whether or not they induced this initial clonal expansion that establishes the
extent of the Barrett’s segment. What is the minimal set of acquired SGAs that are required
for an initial or a subsequent clonal expansion? Individual k had the minimum total amount
of SGA with a maximum of 31 Mb SGA per biopsy. This is a relatively low amount of SGAs
(0.97 % of 3,164 Mb-long human genome) associated with a Barrett’s metaplasia. Could a set
of genomically altered genes present within this 0.97% account for initiation of Barrett’s
metaplasia or is the initial clonal expansion driven by epigenetic modifications of the genome
and/or the changed gastroesophageal reflux microenvironment? These questions warrant
further larger-scale genomic studies that can resolve the etiology of Barrett’s metaplasia and
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potentially advance understanding of disease genesis in other pre-malignant conditions in the
gastrointestinal tract.
Do NSAIDs play a significant role in reducing SGA acquisition rate? While the effect of
NSAIDs is difficult to investigate conditioned on the presence of evolutionary stasis, I
hypothesize that NSAIDs interfere with promotion of clonal expansion of SGA-containing
neoplastic cells. A mechanism of NSAID action may remain elusive of identification,
because the NSAID effect manifests only over 5 or more years of use. It may be the longterm decrease of inflammation that potentially decreases secretion of growth factors of
inflammatory cells present within Barrett’s tissues that stimulate, or promote, clonal
expansion of SGA-containing neoplastic stem cells triggering clonal growth driven by crypt
fission.
All of the studies throughout the studies were based on DNA extracted from biopsies, in
most cases processed by separating BE epithelial cells from stromal cells by an epithelial
isolation technique. Assuming 6.5 picograms of DNA per diploid cell, 200ng of DNA
corresponds to evaluating a mixture of the DNA of approximately 30,769 cells and for
samples having lots of SGAs 200ng of DNA would alter the 30,769 estimate d epending on
the SGA loss to gain ratio. Therefore, since single cell genomics has not been feasible, all of
my results and analyses are at the level of a biopsy, or a mean genotype of 30,000 cells.
Further advancements in single cell genomics would allow the in-depth characterization of
genetic diversity within a biopsy.
Future work could utilize approximate Bayesian computation approaches to match modelgenerated genetic diversity to the experimentally-observed genetic diversity to estimate the
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parameter values able to produce the observed dynamics. I hypothesize that a very low
mutation rate of loci conferring higher crypt reproduction and that a very high reproduction
rate-increasing effect of mutating such loci can produce a punctuated pattern of relative
evolutionary stasis and rare bursts of massive SGAs that are also associated with local clonal
expansions. I hypothesize that selective effects are probably very high, but it is very rare to
achieve an aneuploid, massive SGA, clone that is stable and able to locally expand within the
tissue.
In summary, the results in Chapter 4 will be of general interest to the scientific and medical
community for the following reasons. Never before has neoplastic progression been studied
in such detail, with 12+ biopsies over 5-8 time points and up to 19 years of follow -up within
the same patients, using a whole genome assay. I found that aspirin and other NSAIDs,
which are commonly available and cost effective medications, may exert their cancer
preventive effect through lowering SGA rate. I found that the Barrett’s segment in Barrett’s
esophagus individuals can remain in relative evolutionary stasis over decades of follow-up
where only 0.6 and 7.8 SGAs may occur per biopsy, per genome, per year while on-NSAIDs
and off-NSAIDs, respectively, suggesting an explanation for the low rate of progression for
most Barrett’s esophagus individuals. I demonstrated a new method for estimating somatic
mutation (SGA) rates in vivo, in humans, which can be applied to any neoplasm with
longitudinal samples (showing how evolutionary biologists can make fundamental
contributions to cancer biology). I demonstrated a new, and fundamentally different, type of
biomarker that measures the evolutionary dynamics of progression (SGA rate) not just the
presence or absence of an abnormality. With longitudinal data spanning 6.4-19 years, I
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showed the genome-wide distribution patterns of SGAs over the evolutionary (natural)
course of cancer development.
Finally, rapidly advancing sequencing technologies allow the measurement of the state of the
entire genome. In the clinic, I would recommend that the detection of stable versus unstable
genomes can help manage treatment options in individuals with Barrett’s esophagus and
other pre-malignant conditions. I would also recommend that NSAIDs may be used for
reducing the rate of SGA acquisition in individuals with Barrett’s esophagus. I believe it is
feasible that future randomized controlled trials for cancer chemoprevention or prevention
based on changes in diet and lifestyle could use measurements of evolutionary dynamics, for
instance, changes in the level of somatic genomic abnormalities and phylogenetic tree shape
imbalance both indicating emergence of malignant cell lineages, as intermediate endpoints of
effectiveness.
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Appendix
List of Figures
Figure 1.1. Barrett's specialized intestinal metaplasia and mucosal defense. Barrett's
metaplasia arises in an environment of chronic reflux in which the distal esophagus is
exposed to high levels of local and systemic damage from acid, bile, and tobacco
products, as well as inflammatory responses to the injury [5,9–14]. All are mutagenic.
Barrett's metaplasia has a number of defenses against this mutagenic environment that
are not found in esophageal squamous epithelium [5,15]. A, Barrett's metaplasia
secretes anions, including bicarbonate, that participate in buffering acid reflux [16]. B,
Barrett's metaplasia is a well differentiated epithelium with crypt architecture in which
putative stem cells residing at the base give rise to proliferating transient amplifying
cells and differentiated cells that are sloughed into the lumen. This architecture has
been proposed to be tumor-suppressive because mutations in transient amplifying or
differentiated non-stem cells will be shed from the body before they can accumulate the
serial mutations that lead to cancer [17]. C, Barrett's metaplasia secretes a thick adherent
mucus that is not present in squamous esophageal epithelium for defense against acid
and bile reflux [18–21]. D, Barrett's esophageal cells maintain physiological intracellular
pH after prolonged and repeated reflux exposure [22]. E, The tight junctions of
Barrett's metaplasia overexpress claudin 18 and several other claudins (including
claudins 1, 4, 12, and 23) that provide protection against acid permeation [23]. F, A
combined expression and proteomics study of Barrett's metaplasia reported
overexpression of genes involved in mucosal defense and repair [24]. Figure and figure
legend adapted from Reid et.al. [8]. ................................................................................................... 4
Figure 1.2. Typical Barrett’s segment length remains about 5cm during endoscopic
surveillance. Segment length data over time represents 248 individuals with BE from
the Seattle Barrett’s Esophagus Program cohort. Each point represents an estimate of
the distance between measured lower esophageal sphincter (LES) and ora serrata (OS)
that are recorded at an endoscopy (out of 489 total) and that are proxies for the extent
of the Barrett’s segment. Over all 489 endoscopies, the typical Barrett’s segment length
measures 5.7 ± 3.6cm (mean ± s.d) and linear (blue line) and local weighted linear
regressions (red curve) show that segment lengths stay relatively constant over time...... 6
Figure 2.1. Ratio between R of two blood samples and one gastric sample used as reference
samples and the same Barrett’s sample. The signal profiles look similar and fragile site
FRA3B is deleted in the Barrett’s sample and intact in all 3 reference samples. The only
difference between the reference samples is DNA concentration, where samples “blood
1”, “blood 2”, and “gastric” had 35ng, 104ng, and 200ng of DNA extracted and
analyzed with Illumina 317K SNP arrays. The variation in the amount of DNA used for
the genotyping assay induces a genomic waviness artifact similar to that described in
Diskin et al. [75].....................................................................................................................................25
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Figure 2.2. Total normalized signal intensity R increases if the SNP probes have higher GC content. Shown are all SNPs on chromosome 1 from BE sample #1. The Pearson
correlation between probe %GC and R was 0.57 for these data. ..........................................27
Figure 2.3. As input DNA amount increases, the correlation between probe GC content and
total signal intensity R decreases. All 12 BE samples had various amounts of input
DNA and at low amounts of input DNA (50ng or below) the signal from the arrays
appears noisier and the effect of probe GC content was stronger. The Pearson
correlation was -0.89 for these data. Note that the Pearson correlation for sample #1
that had 49ng of input DNA is 0.57 as shown in Figure 2.2. .................................................28
Figure 2.4. HumanHap300 (317k) array analysis of BE biopsies at the same level (±1cm)
from one patient over 4 endoscopies from 1989 to 2006. In 1989 the BE consensus
FRA3B region showed a region of 1-copy loss (b) flanked by 2-copy loss (a), with an
adjacent region of 1-copy loss (c). In 1993 (a and b) merged into a region of uniform 2copy loss (f), flanked by new regions of 2-copy (d) and 1-copy (e) loss. In 2006 the
region of 1-copy loss at (c) lost its second copy (g). Adapted from Lai, Kostadinov, et
al. [76]........................................................................................................................................................29
Figure 2.5. The same genomic region extended to 61.2 Mb, with a different set of samples
from the same individual show progressive copy loss at various locations within the
site. Adapted from (Brian J Reid, Kostadinov, and Maley 2011)...........................................30
Figure 2.6. Benign clonal evolution in 1 patient with Barrett's esophagus studied
longitudinally over 16 years. Purified Barrett's epithelium from endoscopic biopsies was
assayed with Illumina 317K SNP arrays and compared with a blood sample control. A,
Copy number analysis, normalized by SNP intensities from blood, reveals a single copy
loss at CDKN2A in samples 2 (data not shown) and 3 in 1989, but homozygous
deletion in CDKN2A in sample 1 and all samples from subsequent years. At first
endoscopy in 1989, 2 clones were detected (1 with a small deletion of 1 allele at the
CDKN2A locus, and the other with copy neutral LOH of the entire 9p arm with the
CDKN2A deleted allele, generating biallelic deletion at CDKN2A). B, the SNP allele
frequencies reveal a focal deletion in the CDKN2A locus in samples 2 and 3 in 1989,
but sample 1 included a mixture of the clone from samples 2 and 3 with a new clone
with copy neutral LOH of 9p and biallelic deletion of CDKN2A. All samples from
1993 and later show that the clone with biallelic deletion of CDKN2A went to fixation,
leading to random noise in the allele frequencies for the SNPs in that region, as seen in
the vertical ("waterfall") band in the bottom panel of B. The fact that the rest of the 9p
arm remains diploid can be seen in the copy number data (A). C, The clone with
deletion of the single allele of CDKN2A, which extends past 22.5 Mb on chromosome
9p, also had a single deletion in fragile site FRA3B at 60.42 Mb that distinguishes it
from the other clones. This and other lesions of the clone in samples 2 and 3 were not
observed again after 1989, suggesting that this clone was driven to extinction by the
clone from sample 1, with biallelic deletion of CDKN2A. D, A Camin-Sokal maximum
parsimony reconstruction of the genealogy of clones based on the polymorphic copy
number of lesions in 283 loci across the entire genome in the Barrett's biopsies shows
that only one large clonal expansion occurred between 1989 and 1993. After 1993, the
Barrett's segment remained stable, with accumulation of small interstitial lesions but no
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clonal expansions, no aneuploidy, and no progression to cancer. Figure adapted from
Reid et al. [8]. ..........................................................................................................................................31
Figure 2.7. Output from Illumina’s BeadStudio LOHPlus module showing allele frequencies
in 3 samples. A normal sample (top) shows no LOH at p16 (red rectangle). In 1989 a
small deletion of a single allele at p16 has appeared in all samples (middle). By 1993, all
samples have lost both alleles of p16, with the original localized deletion (now apparent
by a band of background readings with random allele frequencies) and loss of the entire
arm of 9p in for other allele. ..............................................................................................................32
Figure 2.8. Example output from STAC from a subset of the 42 individuals that showed
chromosome 9p alterations and analyzed with 33K-SNP arrays and the union of all
alterations from 12 biopsies from one BE individual analyzed with 317K-SNP array.
Gray bars represent genomic regions on chromosome 9p that are significantly altered
across samples. This plot excludes the BAC array data from 72 patients. ..........................36
Figure 2.9. dChip-generated raw signal intensity images from two BE samples evaluated with
Affymetrix SNP6.0 at the VMSR facility. ......................................................................................39
Figure 2.10. dChip-generated raw signal intensity image (from the green fluorescence
channel) from four BE samples evaluated with Illumina OmniQuad 1M at the FHCRC
genomic facility. .....................................................................................................................................41
Figure 2.11. Double copy loss can be detected in an epithelial-isolated half-biopsy and can be
miscalled as single copy loss in its paired whole half-biopsy. Every point represents a
single SNP probe from 20-24 Mb on chromosome 9. On chromosome 9, the tumor
suppressor gene CDKN2A lies between 21.96 and 21.99 Mb and both the epithelialisolated half-biopsy (upper panel) and the whole half-biopsy (lower panel) show
somatic loss in that chromosomal region. The log ratio between the epithelial-isolated
sample and the blood control sample was -2.0 or lower, whereas the log ratio between
the whole biopsy and the blood control sample was about -0.5. A two-fold lower signal
intensity (log ratio of -2.0 or lower) in the epithelial-isolated sample would easily be
called a double copy (homozygous) loss by an SGA calling algorithm, however a log
ratio of -0.5 in the whole sample would be easily miscalled as a single copy loss. ...........42
Figure 2.12. Copy neutral LOH can be detected in both epithelial-isolated half-biopsy and its
paired whole half-biopsy. The B allele frequency of both half-biopsies show that the
entire region 20-24 Mb of chromosome 9 has LOH, and since the signal intensity log
ratio in .......................................................................................................................................................43
Figure 3.1. Plausible scenarios for genetic diversity dynamics. Genetic diversity can decrease
periodically due to clonal expansions; for instance, if five necessary, sufficient, and ratelimiting steps (mutations) are acquired sequentially in the neoplastic cell population and
boost fitness enough to cause five clonal expansions, they may homogenize the
neoplasm and produce five troughs in genetic diversity (solid line). Such oscillating
dynamics can be captured only with longitudinal data so that troughs in genetic
diversity can be detected. Alternatively, genetic diversity can increase monotonically
over time and modeled as a linear function of time (dashed line). Alternative
hypotheses, such as a single genetic catastrophe or a critical phase transition point, can
also be plausible, in this example, reduced to a simple sigmoid curve (dotted line).
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Importantly, at time of detection of a new tumor, measurement of genetic diversity and
prior knowledge of the typical dynamics of genetic diversity taken together can estimate
the time elapsed since tumor initiation and predict the waiting time for tumor
progression to cancer. Elapsed time since initiation and waiting time to cancer are
clinically relevant variables for diagnostic purposes and for weighing treatment options.
.....................................................................................................................................................................52
Figure 3.2. A spatially-structured crypt population induces monotonic increase in genetic
diversity. Genetic diversity is computed by taking a random sample of 100 individual
crypts from the grid. The neutral mutation for the displayed parameter sweeps is 10 -4.
Black lines represent crypt division-dependent mutation (a=1) and red lines represent
time-dependent mutation (a=0). Each parameter sweep was run in triplicate. .................60
Figure 3.3. A fully-mixed crypt population induces periodic decreases in genetic diversity.
Genetic diversity is computed by taking a random sample of 100 individual crypts from
the grid. The neutral mutation for the displayed parameter sweeps is 10 -4. Black lines
represent crypt division-dependent mutation (a=1) and red lines represent timedependent mutation (a=0). Each parameter sweep was run in triplicate. ...........................61
Figure 3.4. Biopsy sampling (n=12) for a fully-mixed crypt population, where biopsy size
was 10x10 crypts and mutation detection threshold was 0%..................................................62
Figure 3.5. Biopsy sampling (n=12) for a fully-mixed crypt population, where biopsy size is
10x10 crypts and mutation detection threshold is 5%. The neutral mutation for the
displayed parameter sweeps is 10-4. Black lines represent crypt division-dependent
mutation (a=1) and red lines represent time-dependent mutation (a=0). Each parameter
sweep is run in triplicate......................................................................................................................63
Figure 3.6. Example grid spatial dynamics from year 5-20 (7 panels left to right), when
selective mutation rate is 10-6 and neutral mutation rate is 10-4. A fully-mixed crypt
population has quicker genetic diversity dynamics than a spatially-structured crypt
population. The grid state over time is displayed in colors, where crypts are colored by
the genetic similarity based on neutral mutation patterns (principal components analysis
reducing 100 neutral loci to three red, green, and blue dimensions, first row) and by the
number of selective mutations they have acquired (magenta to red, second row). Clones
expand locally driven by acquisition of fitness-increasing SGAs and neutral SGA
hitchhike on the clonal expansions forming complex patterns according to crypts’
phylogenetic histories...........................................................................................................................63
Figure 4.1. Hypothesis and study design for evaluating the NSAID effect on clonal evolution
in Barrett’s esophagus (BE). (Panels A, B) BE is a condition in which the normal
stratified squamous epithelium (white) of the distal esophagus is replaced by specialized
intestinal metaplasia (colors). During endoscopic surveillance (0-20 years, x-axis), the
anatomical landmarks gastroesophageal junction (GEJ) and “ora serrata” (OS) define
the lower (distal) and upper (proximal) boundaries of the Barrett’s segment (y-axis),
respectively. The mean distance between GEJ and OS is 5 cm in our cohort, and
typically remains constant in size throughout 0-20 years of follow-up time. While the
origin and initiation of BE is debated, we followed the model of Wang et al. where BE
is thought to arise at GEJ from a residual embryonic population [118]. This initiation
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model is also consistent with observations of a columnar, secretory epithelium that
forms superficial esophageal glands before being displaced by stratified squamous
epithelium during embryonic development [119]. We estimated that the mean length of
the initiation period in BE is 5.81 years by measuring crypt density and fraction of
branching crypts and assuming a single progenitor crypt and logistic population growth
of crypts by crypt fission (Supplementary Table 4.1). Somatic genomic abnormalities
(SGA) that confer a selective advantage give rise to clones that increase in frequency in
the neoplasm over time (adaptive SGAs, yellow to blue colors). SGA that are selectively
neutral give rise to clones that fluctuate in frequency in the neoplasm over time by
genetic drift (neutral SGAs, gray). (Panel A) In the absence of NSAID use, clonal
evolution is fueled by acquisition of SGA. Chromosomal instability (red unstable clone)
can lead to increased clonal genetic diversity and progression to cancer. (Panel B) We
hypothesized that long-term NSAID use lowers the rate of SGA acquisition. (Panel C)
To test this hypothesis, we evaluated 13 individuals with BE, eleven of whom were not
using NSAIDs (off-NSAIDs) for 6.2 ± 3.5 years (mean ± standard deviation) and then
began using NSAIDs for 5.6 ± 2.7 years, and two of whom were using NSAIDs for 3.3
± 1.4 years and then discontinued use for 7.9 ± 0.7 years. Frozen biopsies were assayed
from 5–8 endoscopies from each individual, marked with x’s. The DNA from 161 BE
biopsies and 13 blood samples was analyzed using 1M SNP arrays to detect SGA. .......89
Figure 4.2. The mean number of detected somatic genomic abnormalities (SGA) and the
amount of the genome they affect remain approximately constant over time in Barrett’s
esophagus. (Panel A) Solid lines connect the means at each time point for all individuals
(a-m), where the symbols a-m are plotted at the end of the lines. The mean number of
SGAs per biopsy-genome per time point was 1,082 ± 177, 1,844 ± 573, and 1,154 ±
746 (mean ± standard deviation) in individuals b, f, and j, respectively, compared to 279
± 86 in the rest of the individuals. In this instance, number of SGAs is an individualspecific estimate of the total number of independently acquired SGA events and is
computed by counting the number of abnormal genomic segments identified by the
union set of all detected SGA break points across samples of a given individual (See
GLAD segmentation and SGA detection in Methods). (Panel B) The mean amount of
genome affected by SGA per time point was 119 ± 79 Mb, 242 ± 121 Mb, and 227 ±
222 Mb for individuals b, f, and j, and 53 ± 30 Mb for the rest of the individuals. .........90
Figure 4.3. The effect of NSAIDs on appearance and regression of SGA events. (Panel A)
NSAID use is associated with appearance of fewer new SGA events. For this analysis,
we excluded all SGAs present at baseline because they had occurred and increased in
frequency for an unknown amount of time prior to detection at baseline and since we
have self-reported NSAID use information reaching back only 6 months prior to
baseline. We counted only new SGAs that appeared within the off-NSAID or onNSAID periods. (Panel B) NSAID use is associated with a decrease in detectable cell
populations with pre-existing SGAs. For this analysis, we restricted the analysis to only
the SGAs not detected in the final endoscopy in order to count their regression during
either the on-NSAIDs or off-NSAIDs periods. (Panels A, B) We binned newly
appearing or regressed pre-existing SGA according to lesion size (0 bp–100Mb, x-axis),
but detected no apparent effect of NSAID use on selection for or against lesions of a
specific size category; rather, NSAID use affected all size categories of SGAs equally.
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(Wilcoxon rank-sum test, 2-sided p-values, *** p<0.01, ** p<0.05, * p<0.1, solid bars
and associated error bars represent mean and standard deviation of newly appearing
and regressing SGAs per biopsy). ....................................................................................................91
Figure 4.4. Clonal evolution in individuals b and j. (Panel A) Solid lines connect the mean
amount of SGA detected across biopsies at each time point. Dots correspond to
biopsies taken during follow-up (x-axis) that have total SGA detected by SNP arrays (yaxis). In individual b (black line), we observed evolutionary stasis, where the mean
amount of SGA was 119 ± 79 Mb over more than a decade of follow -up. In individual
j (red line), we observed evolutionary stasis up to year 7, which was disrupted by a
massive burst of SGA detected in year 8.5. Three years after the appearance of this
massively altered clone, individual j progressed to esophageal adenocarcinoma.
Individual b started NSAIDs after year 5, while individual j started regular NSAIDs use
only after year 10. (Panels B and C) Genome-wide view of SGA over time in
individuals b and j. Each ring, labeled with a biopsy number, represents whole-genome
SGA data from a different biopsy. Thin black line rings separate endoscopies (time
points), white background shows time periods off-NSAIDs and gray background
shows time periods on-NSAIDs. Within the rings, black segments designate
homozygous deletion, red single copy loss, orange copy-neutral LOH, and green shows
copy gain. (Panel B) Circos plot of SGA in individual b. Note the appearance of “new”
whole chromosome LOH at chromosome 6 and 11 in biopsy 5, taken during the offNSAIDs period, and the detection of a clone lacking alterations on chromosomes 4, 12,
17 and 20, in biopsies 9 and 7, taken during the on-NSAIDs period. (Panel C) Circos
plot of SGA in individual j. A massive burst of SGAs was detected first in biopsy 8, in
year 8.5, before the individual began regular NSAID use. Biopsy 2 (second inner ring),
taken at the baseline endoscopy 8.5 years prior to the burst, shared a subset of the
SGAs seen in the massively altered clone (chromosomes 10, 12, 17 and 18), and thus is
likely to be an early, ancestral progenitor of the massively altered clone. (Panels D and
G) Consensus phylogenetic trees estimated by BEAST reveal long-term co-existence of
clones. Branch lengths are scaled according to time, the tips of the phylogeny are
biopsies aligned on the x-axis according to their sampling time, and all internal nodes
are estimated coalescence times assuming a logistic population growth model (see
Methods and Text S1). Dashed gray line represents the onset of NSAID use. In
participant j, we detected 1,215 SGAs affecting 211 Mb of the genome in biopsy 2, the
likely progenitor clone that presaged the appearance of 2,357 SGAs affecting 578 Mb
of the genome in biopsy 8, 8.5 years later. In participant b, biopsies 7–10 have few
SGAs and only a small amount of genome affected by SGA. (Panels E, F, H, I)
Maximum parsimony trees estimated by PAUP reveal the ancestral relationships among
biopsies based on shared SGA characters. Branch lengths are scaled according to
estimated number of SGAs (Panels E, H) or the amount of genome affected by SGA
(Panels F, I). ............................................................................................................................................92
Figure 4.5. Clonal evolution in participants l and f. (Panel A) In individual l (black), the mean
amount of SGA was 54 ± 29 Mb over time, whereas in individual f (red) the mean
amount of SGA was 242 ± 121 Mb over time. (Panels B and C) Genome-wide view of
SGA over time in individuals l and f. (Panel B) During the off-NSAID period in
individual l, we detected a whole-chromosome gain of chromosome 8 in biopsy 12
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(green band) and some copy-neutral LOH events on chromosome 1 in biopsies 9 and
11 (orange bands). (Panel C) We detected 1,844 ± 573 of SGAs in individual f, who did
not progress to EA, but rather opted for esophagectomy for high-grade dysplasia after
6.4 years of follow-up and subsequently died of mesothelioma 11.9 years later. (Panels
D, G) Consensus phylogenetic trees estimated by BEAST reveal long-term co-existence
of multiple clones. (Panels E, H, F, I) Maximum parsimony trees reveal an underlying
progressive evolution of SGA events irrespective of time. Note in individual f that the
clade defined by biopsies 1, 7, and 9 seem the most advanced in progression.
Consensus phylogenetic trees generated as indicated in the legend to Figure 4. ..............94
Figure 4.6. BEAST analysis of the SGA patterns across longitudinal biopsies within
individuals suggests that NSAID use reduces the SGA rate (number of SGA events per
genome, per year). For all individuals (a-m), the mean off-NSAID SGA rate was 7.8
(95% support interval [SI]: 7.1–8.6) and the mean on-NSIAD SGA rate was 0.6 (95%
SI: 0.3–1.5). For participants a-k, the mean off-NSAID SGA rate was 8.8 (95% SI: 8.1–
9.5,), whereas the mean on-NSAID SGA rate was 0.2 (95% SI: 0.03–1.0). For the two
participants l and m that started surveillance on NSAIDs and then went off NSAIDs,
there are mixed results. The mean on-NSAID SGA rate for individual l was 3.1 (95%
SI: 2.2–4.7) and the mean off-NSAID SGA rate was 4.4 (95% SI: 3.1–5.9). However,
for individual m the mean on-NSAID SGA rate was 2.5 (95% SI: 2.1–3.0) and the
mean off-NSAID SGA rate was 0.1 (95% SI: 0.01–0.6). .........................................................95
Supplementary Figure 4.7. Circos plots of individuals a,c,d,e,g,h,i,k, and m. Each ring
represents whole-genome SGA data from a different biopsy. Thin black line rings
separate endoscopies (time points), white background shows time periods off-NSAIDs
and gray background shows time periods on-NSAIDs. Within the rings, black segments
designate homozygous deletion, red single copy loss, orange copy-neutral LOH, and
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Supplementary Figure 4.8. Estimated trees by BEAST for individuals a-m. Branch lengths
are scaled according to time, the tips of the phylogeny are biopsies aligned on the x-axis
according to their sampling time, and all internal nodes are estimated coalescence times
assuming a logistic population growth model (see Methods). Dashed gray line
represents the time point of change in NSAID use. All these trees show long-term coexistence of clones and no evidence of a clonal expansion taking over the Barrett’s
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Supplementary Figure 4.9. Estimated trees by PAUP trees where branch lengths represent
estimated number of SGA events for individuals a,c,d,e,g,h,i,k and m. The topology of
these trees suggest progressive accumulation of SGAs. ...........................................................98
Supplementary Figure 4.10. Estimated trees by PAUP trees where branch lengths represent
the total amount of SGA (Mb) of the estimated 0->1 SGA events from Supplementary
Figure 3 for individuals a,c,d,e,g,h,i,k and m. ...............................................................................99
Supplementary Figure 4.11. Linear chromosome plot of SGAs that are common across all
biopsies within an individual. The most likely regions affected by SGA are fragile sites
FHIT and WWOX on chromosomes 3 and 16, respectively, as well as the p-arm of
chromosome 9 that often includes the tumor suppressor gene CDKN2A. These are
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lesions that were present by the time of the first endoscopy and so may have been
established with the hypothesized initial expansion of Barrett’s epithelium in
competition with squamous epithelium. ..................................................................................... 100
Supplementary Figure 4.12. Linear chromosome plot of detected somatic genomic
abnormalities (SGAs) in biopsies from the baseline endoscopy (top panel), the first
sampling period (off-NSAIDs for a-k and on-NSAIDs for l, m; middle panel), and the
second sampling period (on-NSAIDs for a-k and off-NSAIDs for l, m; bottom
panel).This plot shows the genomic location and size of newly detected SGAs during
off-NSAID (red) and on-NSAID (green) periods that are summarized in Figure 3A.
Black bars represent SGAs observed in a prior sampling period or at baseline; top panel
– black represents SGAs detected in any biopsy from the baseline endoscopy; middle
panel – black represents SGAs detected in any biopsy from baseline endoscopy that is
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that is also detected in at least one biopsy in the second sampling period. In the middle
panel, red and green bars represent newly acquired SGAs that are detected in at least
one biopsy in the first sampling period, but not detected at baseline. In the bottom
panel, red and green bars represent newly acquired SGAs that are detected in at least
one biopsy in the second sampling period, but not detected in any biopsy from baseline
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Supplementary Figure 4.13. Raw data segmentation and SGA calls for all 161 biopsies of
individuals a–m. Every page shows an individual biopsy and has 5 panels (top to
bottom): first panel, raw Log 2R ratio between biopsy and leukocyte control, where gray
SNPs are homozygous SNPs and black SNPs are heterozygous SNPs; second panel,
GLAD segmentation of homozygous SNPs (blue line) and heterozygous SNPs (red
line); third panel, raw mBAF (reflected and scaled B Allele Frequency of the BE
sample) where homozygous SNPs are shown in gray, and heterozygous SNPs are
shown in black; fourth panel, GLAD segmentation of the mBAF data of heterozygous
SNPs, which are informative for allelic imbalance; fifth panel, final SGA calls for
chromosomal regions: GN (copy gain, green), CNLOH (copy neutral LOH, orange),
SD (single deletion, or single copy number loss, red), HD (homozygous deletion, or
double copy number loss, black). Only one example biopsy is displayed here, which is
biopsy #8 from individual j, which shows massive SGA...................................................... 106
Figure 5.1. Study design of single cell experimental evolution. Single cells from an ancestral
cell population from a CP-D Barrett’s cell line were grown in 96 well plates, where cells
were plated at a concentration of 1/3 of cells per well. Cells were passaged into larger
6-well plates and T25 and T75 plates as they grew in number. After two rounds of
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evaluated with Illumina 550K arrays at the Penn Hospital of the University of
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